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The biological fitness of a pathogen is defined as its ability to reproduce, survive, cause disease 
and be transmitted. Drug-resistant M. tuberculosis isolates often exhibit reduced competitive 
ability against susceptible isolates in the absence of drug selection. However, compensatory 
mutations may, to some extent, offset fitness costs associated with resistance-conferring 
mutations. Most studies to date have focused on the fitness of isogenic laboratory strains or 
globally-relevant strains. Fewer studies have addressed the fitness of endemic strains which 
propagate in multidrug and extensively drug-resistant forms (MDR and XDR, respectively). In 
this study, the fitness of four genotypes which drive the transmission of tuberculosis (TB) in 
KwaZulu-Natal (KZN), South Africa was explored. This included F15/LAM4/KZN genotype 
strains, some of which were involved in the notorious XDR-TB outbreak in Tugela Ferry, KZN 
as well as Beijing, F11 and F28 genotype strains. Drug-resistant F15/LAM4/KZN and F28 
genotype strains demonstrated increased in vitro fitness, whilst Beijing and F11 MDR strains 
had markedly reduced fitness. These findings correlated with whole-genome and Sanger 
sequencing data which revealed the presence of low/no-cost resistance-conferring mutations as 
well as intra- and intergenic compensatory mutations in drug-resistant F15/LAM4/KZN and F28 
strains, respectively. In contrast, high cost katG mutations and no accompanying compensatory 
mutations were identified in Beijing and F11 MDR strains. During co-culture experiments, a 
novel observation was made whereby susceptible and resistant strains exhibited synergistic 
growth compared with axenic cultures i.e. in vitro trans-complementation. Drug-resistant 
F15/LAM4/KZN strains did not undergo fitness costs in THP-1 macrophages and produced 
increasing levels of TNF-α which may enhance tissue destruction and dissemination to other 
hosts. Although demonstrating similar intracellular fitness, susceptible and MDR Beijing, F11 
and F28 strains induced heterogeneous cytokine responses. Thus, the lack of a direct 
relationship between bacillary burden and cytokine responses indicates that this diversity results 
from strain heterogeneity. Relapse isolates, including those from F15/LAM4/KZN and Beijing 
genotypes, may reactivate without any changes in biological fitness, thereby retaining the 
potential to re-transmit. Taken together, the enhanced fitness of drug-resistant F15/LAM4/KZN 
and F28 genotype strains is due to the presence of beneficial mutations, while the reduced 







































1.1  INTRODUCTION 
 
The World Health Organization (WHO) reported approximately 9.6 million cases of tuberculosis 
(TB) globally in 2014 (WHO 2015). Mycobacterium tuberculosis is the etiologic agent of TB and is 
spread from person-to-person in the form of aerosolised droplets. Although one third of the human 
population is thought be infected with this pathogen, most individuals develop latent or 
asymptomatic TB (Lin and Flynn, 2010) and only 5-10% of infected individuals progress to active 
disease. Co-infection with the human immunodeficiency virus (HIV) and the rise in drug resistance 
pose significant threats to the control of TB (Raviglione and Smith, 2007; Chindelevitch et al. 
2015), particularly in sub-Saharan Africa. In South Africa, nearly 80 % of the population are 
latently infected with TB and over 70 % of individuals with active disease are co-infected with HIV 
(National Strategic Plan 2012-2016).  
 
A small population (2-5 %) of treated TB patients go on to develop recurrence, further complicating 
TB epidemics (Weis et al. 1994; Tuberculosis Trials Consortium, 2012). This may be due to 
reactivation of the initial infection (termed relapse) or reinfection with another M. tuberculosis 
strain (Sonnenberg et al. 2001; Verver et al. 2005). Using DNA fingerprinting, a recent study 
showed that relapse arose early after completion of anti-TB treatment while reinfection occurred 
after 12 months and constituted nearly 50 % of recurrent TB cases (Marx et al. 2014). Retreatment 
cases are often associated with increased costs which may prove problematic for developing 
countries with limited national TB budgets (Panjabi et al. 2007).  
 
The diagnosis and treatment of TB remains a growing challenge, especially in patients who are 
infected with drug resistant strains of M. tuberculosis. Drug resistance can arise as a result of 
acquired resistance i.e. the selection of resistant M. tuberculosis populations during inadequate 
treatment regimens or by primary resistance i.e. infection with a resistant TB strain. In 2014, 4700 
(3700-5900) new TB cases in South Africa were attributed to multidrug resistance (MDR) (WHO, 
2015). Many studies have documented primary resistance as a major contributor to the increase of 
MDR-TB in South Africa (van Rie et al. 1999; Victor et al. 2007; Strauss et al. 2008; Johnson et al. 
2010; Cox et al. 2010; Royce et al. 2013; Gandhi et al. 2014).  
 
Extensively drug-resistant (XDR)-TB was first discovered in South Africa in 2006 (CDC, 2006). To 
put into perspective the enormity of XDR-TB in South Africa, incidence rates in this country are 
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said to be higher than total TB incidence rates in some low-incidence countries e.g. the United 
States (Lim et al. 2015). Treatment for MDR-TB can last up to 20 months, compared with 6 months 
for drug-susceptible TB (WHO 2015) and becomes progressively difficult in patients with XDR-TB 
and of recent, totally drug-resistant (TDR)-TB, as these regimens require the use of added drugs, 
posing considerable side-effects to patients (Banerjee et al. 2008; Dheda et al. 2014). If 
implemented properly, new drugs (i.e. bedaquiline) and treatment regimens may improve MDR- 
and XDR-TB outcomes, especially in South Africa which, together with the Russian Federation 
represent 75 % of MDR-TB patients currently being treated with bedaquiline (WHO, 2015). 
 
Whereas most bacteria exploit mobile genetic elements for the propagation of drug resistance, M. 
tuberculosis acquires drug resistance through chromosomal mutations and gene rearrangements 
(Sandgren et al. 2009). Drug-resistant strains often demonstrate decreased competitive ability (or 
‘fitness costs’) against susceptible strains in the absence of the drug (Gagneux et al. 2006). This 
‘fitness cost’ is dependent on strain genetic background and specific drug resistance-encoding 
mutations which may be improved by compensatory mechanisms (Cohan et al. 1994; Schrag et al. 
1997; Bottger et al. 1998; Reynolds 2000; Bjorkman et al. 2001; Maisnier-Patin and Andersson, 
2004; Gagneux et al. 2006). Compensatory mutations play a significant role in the transmission of 
MDR and XDR-TB strains (Comas et al. 2012; de Vos et al. 2013; Casali et al. 2014; Cohen et al. 
2015) and represent a key area of interest in TB research.  
 
Much of the sequence diversity in M. tuberculosis is  ascribed to inherent and acquired drug 
resistance (reviewed in Köser et al. 2012), with various public databases providing an informative 
platform for comparative analysis of resistance-encoding mutations in global M. tuberculosis 
strains. While whole-genome sequencing (WGS) efforts have substantially improved our 
understanding of compensatory mutations, transmission chains, estimation of mutation rates and 
phylogenetic classification, this method can be limited if not supported by additional data which 
exemplify clinical properties of M. tuberculosis strains (Takiff and Feo, 2015).  
 
Most studies to date have focused on the fitness of isogenic laboratory strains or globally-relevant 
strains. Fewer studies have addressed the fitness of endemic strains which propagate in MDR and 
XDR forms i.e. the F15/LAM4/KZN genotype which was responsible for the XDR-TB outbreak in 
Tugela Ferry, KwaZulu-Natal in 2005 (Gandhi et al. 2006). This is the first study investigating the 
in vitro fitness of the F15/LAM4/KZN strains, as well as other relevant, genotype families including 
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Beijing, F11 and F28. These genotypes circulate within the KwaZulu-Natal Province– a region of 
South Africa with the second highest number of inhabitants (~10.3 million) of which 11.2% is 
infected with HIV (South African Statistics, 2015).  
 
While the detection of low- or no- cost mutations and compensatory mutations among clinical M. 
tuberculosis strains has provided insight into drug resistance and fitness, this subject remains 
incompletely studied. Using clinically-relevant strains from KZN, South Africa, this study focused 
on the identification of resistance-conferring mutations and/or compensatory mutations and 
establishing their role in biological fitness. A better understanding on the fitness of MDR and XDR 


























1.2.  LITERATURE REVIEW 
 
1.2.1  M. tuberculosis strain diversity 
Although the M. tuberculosis genome is more highly conserved than other pathogenic bacteria 
(Achtman, 2008), recent data supports that M. tuberculosis complex (MTBC) strains are more 
diverse than previously believed (Gagneux et al. 2007). The advent of genotyping allowed the 
identification of several polymorphisms in the M. tuberculosis genome, including single nucleotide 
polymorphisms (SNPs), large sequence polymorphisms (LSPs) and polymorphisms associated with 
repetitive sequences (Brown et al. 2010). 
 
1.2.1.1  Strain classification 
For a long time, IS6110 restriction fragment length polymorphism (RFLP) was considered as the 
gold standard for genotyping of MTBC strains. One of the noteworthy features of this method was 
its ability to characterise successful strains, based on the quantity and geographical distribution of 
associated TB cases (van Soolingen, 2001; Mathema et al. 2006; Barnes and Donald, 2009). 
Although RFLP typing is still used today, newer genotyping methods utilising polymerase chain 
reaction (PCR) have taken precedence. These include spacer-oligo typing (Spoligotyping) and 
mycobacterial interspersed repetitive unit variable number tandem repeat (MIRU-VNTR) typing 
(Supply et al. 2000; Supply et al. 2001). Despite their usefulness in epidemiological studies, these 
standard genotyping techniques are variable in terms of their discriminative power and have a 
tendency for convergent evolution (Comas et al. 2009).  
 
Given that horizontal gene transfer does not occur with MTBC and deleted regions within a 
particular strain cannot be regained, another method known as genomic deletion analysis was 
developed to classify strains on account of LSPs. Based on this analysis, MTBC was later 
categorised into seven major lineages (Hirsch et al. 2004; Mostowy et al. 2004; Tsolaki et al. 2004; 
Gagneux et al. 2006), with Lineages 2 (Beijing) and 4 (Euro-American) being the most 
geographically dispersed and virulent (Coscolla and Gagneux, 2014). Similar to other genotyping 
methods, LSPs fell short during phylogenetic classification of strains, with the introduction of 
whole-genome sequencing (WGS) providing a more robust measure of phylogenetic diversity. This 
next-generation sequencing technology currently exists as the new ‘gold standard’ for M. 




1.2.2.2 Predominant genotypes in South Africa 
The overrepresentation of specific genotype families among cases of drug resistance and 
transmission is of paramount importance in relation to TB control regimens (Marais et al. 2006). In 
South Africa, the majority of MDR- and XDR-TB cases were reported in KwaZulu-Natal (KZN), 
Eastern Cape and Western Cape Provinces (NHLS, 2009). Upon closer inspection, a clear 
association was shown between specific genotypes and the appearance of XDR-TB in these 
provinces, probably as a result of selection by standard treatment regimens (Muller et al. 2013). 
Figure 1.1 depicts the distribution of drug resistance amongst diverse genotype families detected in 
KZN (Cohen et al. 2015), demonstrating a strong association of the F15/LAM4/KZN genotype with 
XDR-TB cases in the KZN Province. This is in agreement with multiple retrospective and/or 
















Figure 1.1 Diverse strains contribute to drug resistance in KwaZulu-Natal. Midpoint rooted 
maximum-likelihood phylogeny of 340 M. tuberculosis isolates. Four of the seven known M. 
tuberculosis lineages were identified: CAS (Lin1), Beijing (Lin2), EAI (Lin3), and Euro-American 
(Lin4). Digital spoligotyping identified 17 unique spoligotypes in the dataset; spoligotypes are 
shown on this figure if they are represented by three or more strains. Phenotypic XDR, MDR, poly-
and monodrug resistance (labelled “Drug resistant other”), and pansusceptible strains are indicated 
by coloured tick marks at the tip of each leaf node (Cohen et al. 2015) 
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The F15/LAM4/KZN genotype was responsible for the Tugela Ferry XDR-TB outbreak, whereby 
52 of 53 HIV- co-infected patients succumbed to death within a median time of 16 days (Gandhi et 
al. 2006). In a more recent examination, LAM4 strains (some of which represented Tugela Ferry 
clone members) were discovered to mutate at an astonishing rate of 0.61 SNPs per genome per year 
– a rate higher than any other reported for M. tuberculosis strains. Similar to a recent study by 
Gandhi et al. (2014), Figure 1.1 illustrates the association of the S genotype with MDR-TB (Cohen 
et al. 2015).  
 
The Beijing genotype was first described by van Soolingen et al. (1995) and belongs to principle 
genetic group 1 on the basis of its katG 463Leu and gyrA 95Thr markers (Sreevatsan et al. 1997). 
The widespread distribution of Beijing strains (Bifani et al. 2002) can be accredited to its increased 
virulence in macrophages and animal models (Manca et al. 1999; Zhang et al. 1999; Manca et al. 
2001; Li et al. 2002; Lopez et al. 2003; Tsenova et al. 2005). The LAM3 genotype on the other 
hand, is found distributed across 4 continents and 25 countries worldwide, and is a major 
contributor to TB in South Africa, particularly in the Western Cape Province (Victor et al. 2004). A 
C-T nucleotide substitution at codon 491 of the rrs gene found not to be associated with 
streptomycin resistance, is actually a useful phylogenetic marker for the F11 genotype (Victor et al. 
2001).  
 
1.2.2 Mechanisms of drug resistance 
The rising epidemic of drug-resistant TB has compromised treatment strategies in various regions 
around the globe (WHO, 2015). Multidrug-resistant TB is caused by strains resistant to first-line 
anti-TB drugs, isoniazid (INH) and rifampicin (RIF) (WHO, 2015). Extensively drug-resistant TB 
is defined as resistance to any fluoroquinolone and injectable drug in addition to MDR-TB (WHO, 
2015). The treatment of XDR-TB requires extended treatment times with expensive and less-
effective second-line drugs, often causing adverse side effects in patients (Pietersen et al. 2014). 
Improved understanding of the mechanisms of drug resistance may help identify novel drug targets 
and enhanced methods of detecting drug resistance (Palomino and Martin, 2014). In the sections 
that follow, mechanisms of action and associated resistance to key drugs will be discussed. Table 
1.1 provides a summary of the mechanisms of drug resistance in current and newly-discovered 





Table 1.1 Anti-TB drugs and mechanisms of drug resistance (adapted from Müller et al. 2013)  
Drug Gene or gene 
region 
Natural function of gene Role in resistance formation 
when mutated 
Isoniazid ahpC Alkyl hyperperoxide reductase Compensatory mutations 
fabG 3-Oxacyl-thioester reductases Unknown 
fadE24 Involved in fatty acid β-oxidation Unknown 
inhA Enoyl reductase Alteration of drug target 
inhA promoter Regulation of expression of inhA Overexpression of drug target 
iniA Efflux pump associated Altered efflux pump activity 
katG Catalase/peroxidase Elimination of pro-drug 
conversion 
Rifampicin rpoA α-Subunit of RNA polymerase Compensatory mutations 
rpoB β-Subunit of RNA polymerase Alteration of drug target 
rpoC β'-Subunit of RNA polymerase Compensatory mutations 
Pyrazinamide pncA Nicotinamidase Elimination of pro-drug 
conversion 
Streptomycin gidB 7-Methylguanosine methyltransferase Alteration of drug target 
rpsL S12 ribosomal protein Alteration of drug target 
rrs 16S rRNA  Alteration of drug target 
Ethambutol embA Arabinosyl transferase Alteration of drug target 
embB Arabinosyl transferase Alteration of drug target 
embC Arabinosyl transferase Alteration of drug target 
embR Regulator of embCAB operon 
expression 
Overexpression of drug target 
iniA Efflux pump associated Altered efflux pump activity  
rmlD dDTP-4-dehydrorhamnose reductase Unknown 
Fluoroquinolones gyrA DNA gyrase Alteration of drug target 
gyrB DNA gyrase Alteration of drug target 
Kanamycin/amikacin rrs 16S rRNA Alteration of drug target 
rrs 16S rRNA  Compensatory mutations 
Capreomycin/viomycin tlyA rRNA methlytransferase Alteration of drug target 
rrs 16S rRNA Alteration of drug target 
Ethionamide inhA Enoyl reductase Alteration of drug target 
inhA promoter Regulation of expression of inhA Overexpression of drug target 
Para-amino salicylic 
acid 
thyA Thymidylate synthase A Elimination of pro-drug 
conversion 
PA-824 and  
OPC-67683 
Rv3547 Hypothetical 16.4 kDa Alteration of drug target 
TMC207 atpE ATP synthase Alteration of drug target 
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1.2.2.1 Isoniazid, rifampicin, ethambutol and pyrazinamide as first-line drugs 
Introduced in the early 1970s, RIF is still currently used as an effective first-line drug against TB. 
RIF exerts its activity against both replicating and non-replicating (slow metabolising) bacteria, by 
binding to the beta (β) subunit of RNA polymerase, thereby impeding the elongation of mRNA 
(Blanchard, 1996). Mutations conferring RIF-resistance primarily occur in an 81-bp region of the 
rpoB gene, also known as the rifampicin resistance-determining region (RRDR) (Ramaswamy et al. 
1998), although mutations in other regions of rpoB have been described as well (Heep et al. 2001; 
Yuen et al. 2011). Single nucleotide polymorphisms in codons in 516, 526 and 531 are most 
frequently observed in RIF-resistant clinical isolates (Caws et al. 2006; Somoskovi et al. 2001). 
Nearly all RIF-resistant isolates have additional resistance to other drugs, particularly INH. Based 
on this finding, RIF is considered a representative marker for MDR-TB (Blanchard, 1996).  
 
Isoniazid is a pro-drug that becomes activated by the action of catalase-peroxidase encoded by the 
katG gene in M. tuberculosis (Zhang et al. 1992). It acts to prevent mycolic acid synthesis in 
metabolically-active, replicating bacteria, via the NADH-dependent enoyl-acyl carrier protein 
reductase which is produced by inhA (Rawat et al. 2003). Whilst resistance to RIF occurs in rpoB 
alone, INH-resistance develops as a result of mutations in one or more genes including katG, inhA, 
kasA, ahpC and ndh. The S315T katG mutation is most frequently detected in clinical isolates and is 
also associated with a high level of INH resistance (MIC > 1 µg/ml) (Vilchèze et al. 2007; Fenner et 
al. 2012). Some M. tuberculosis isolates possess mutations in the inhA promoter region, which act 
to overexpress InhA or reduce its affinity for the INH-NAD adduct (Rozwarski et al. 1998). 
Moreover, inhA mutations have been implicated in resistance to ethionamide (ETH) - a second-line 
drug which shares structural similarities and a common target site to INH (Banerjee et al. 1994; 
Larsen et al. 2002).  
 
Combinations of mutations in inhA regulatory and coding regions were recently shown to induce 
both high-level INH resistance and cross-resistance to ETH (Machado et al. 2013). While the 
involvement of genes and intergenic regions including kasA, oxyR-ahpC and furA-katG in INH 
resistance remains debateable, mutations in ndh have been shown to confer co-resistance to INH 
and ETH (Miesel et al. 1998; Vilcheze et al. 2005; Hazbón et al. 2006; Ando et al. 2011). A 
synonymous mabA mutation was recently shown to cause INH resistance via the overexpression of 




Ethambutol is a bacteriostatic agent which hampers the biosynthesis of arabinogalactan in 
replicating bacteria (Takayama and Kilburn, 1989). The arabinosyl transferase enzyme is encoded 
by three M. tuberculosis genes (embCAB), which are arranged in an operon (Mikusová et al. 1995). 
Ethambutol resistance is commonly associated with the embB mutations, specifically those in codon 
306 (Telenti et al. 1997; Sreevatsan et al. 1997), however some studies have reported its occurrence 
in ethambutol susceptible isolates as well (Ahmad et al. 2007). Although insufficient for causing 
high-level ethambutol resistance, embB306 mutations in combination with others i.e. those in embC, 
Rv3806c and Rv3792 can increase EMB resistance, thereby resulting in a range of ethambutol MICs 
depending on the type and number of mutations (Safi et al. 2013).  
 
Pyrazinamide acts against semi-dormant bacteria present in acidic environments i.e. TB lesions 
(Mitchison, 1985) by inducing cellular damage (Zhang and Mitchison, 2003). Similar to INH, PZA 
is a pro-drug which requires conversion into its active form – pyrazinoic acid (Konno et al. 1967; 
Scorpio and Zhang, 1996). This is facilitated by the pyrazinamidase/nicotinamidase enzyme 
encoded by the pncA gene (Konno et al. 1967; Scorpio and Zhang, 1996). PZA-resistant strains 
commonly harbour mutations in 561-bp or 82-bp regions of the pncA open reading frame or 
promoter region, respectively, however, mutations have been reported in other regions of the pncA 
gene as well (Scorpio et al. 1997; Juréen et al. 2008). Moreover, some PZA-resistant strains lack 
pncA mutations with some studies suggesting a role for the rpsA gene in PZA resistance, although 
data supporting this is limited (Alexander et al. 2012; Simons et al. 2013; Tan et al. 2014). 
 
1.2.2.2  Fluoroquinolones and aminoglycosides as second-line drugs 
Ofloxacin (OFX) and ciprofloxacin are presently utilised as second-line drugs against MDR-TB 
(WHO, 2014), whilst newer quinolones i.e. moxifloxacin and gatifloxacin are being tested for their 
efficacy as potential first-line drugs (Rustomjee et al. 2008; Palomino and Martin, 2013). 
Fluoroquinolones (FQ) inhibit topoisomerase II encoded by gyrA and gyrB genes in M. tuberculosis 
which promote supercoiling of DNA (Takiff et al. 1994; Aubry et al. 2004). Similar to rpoB, gyrA 
and gyrB contain a quinolone resistance-determining region (QRDR), with mutations at codons 90 
and 94 being the most frequently identified (Cheng et al. 2004; Sun et al. 2008). Clinical isolates, 
irrespective of FQ susceptibility, all possess a naturally-occurring mutation at codon 95 (Musser, 
1995). Efflux mechanisms have also been proposed as putative causes of FQ resistance in M. 




Kanamycin (KAN) and amikacin are aminoglycosides used in the treatment of MDR-TB. By 
altering the level of 16S rRNA, these drugs act to inhibit protein synthesis (Alangaden et al. 1998). 
Mutations commonly conferring high-level KAN resistance are found at nucleotide positions 1400 
and 1401 of the rrs gene, and occasionally position 1483 (Alangaden et al. 1998; Suzuki et al. 
1998). Promoter mutations at position -10 and -35 in eis (encodes aminoglycoside acetyltransferase) 
have been found to confer low-level KAN resistance in 80 % of clinical isolates (Zaunbrecher et al. 
2009; Campbell et al. 2011).  
 
1.2.2.3 Implications of drug resistance 
Drug resistance remains a complex process with some resistant strains harbouring uncharacterised 
mutations (Zhang et al. 2013). Implementation of new drugs in anti-TB treatment necessitates the 
responsibility of rapidly ascertaining resistance-conferring mutations to circumvent the evolution of 
resistant strains, thereby preserving the efficacy of new regimens (Trauner et al. 2014). Additional 
research is needed on the role of particular genetic mutations in the acquisition of MDR- and XDR-
TB and its association with strain fitness. Efflux pumps are sometimes up-regulated in drug-
resistant strains during drug selective pressure (Gupta et al. 2010), thus their role in drug resistance 
also warrants further research.   
 
1.2.3 Fitness, epistasis and compensatory evolution 
The concept of bacterial fitness has become an increasingly popular area of interest owing to its 
significant role in shaping the future of MDR and XDR-TB (Cohen and Murray, 2004; Blower et al. 
2004). M. tuberculosis fitness is essentially dependent on the rates at which drug-susceptible and 
resistant populations compete, transmit between hosts and are eliminated from infected hosts, with 
the magnitude of these factors varying according to the degree and pattern of antibiotic usage 
(Andersson and Levin, 1999). Similar to other bacteria, M. tuberculosis strains carrying resistance-
encoding mutations often undergo ‘fitness costs’ (Billington et al. 1999; Mariam et al. 2004; 
Gagneux et al. 2006). This cost is variable as it may depend on the type of mutation or genetic 
background of the strain (Gagneux et al. 2006). Mutations may differ in the level of costs imposed 
and there appears to be a strong selection for low- or no- cost mutations in clinical isolates (Bottger 





Epistasis refers to the phenomenon whereby the phenotypic effect of one mutation differs 
depending on the presence of another mutation (Weinreich et al. 2005). This phenomenon may be 
positive or negative depending on whether the interactions between mutations are beneficial or 
deleterious to the organism. During positive epistasis, the evolution of drug resistance is enhanced 
as the collective cost of resistance-encoding mutations is lower than individual mutations which 
have additive fitness costs (Trindade et al. 2009). This is supported by the finding that specific 
combinations of mutations in rpoB (RIF resistance) and gyrA (OFX resistance) confer fitter status to 
MDR/XDR strains (Borrell et al. 2013). Another example of positive epistasis is the progressive 
development of ethambutol (EMB) resistance in M. tuberculosis where, in addition to embB 
M306V mutations, stepping-stone mutations in Rv3806c are acquired to augment EMB minimum 
inhibitory concentrations (MICs) (Safi et al. 2013). Negative epistasis on the other hand, limits the 
progression of drug resistance by exacerbating fitness costs (Trindade et al. 2009).  
 
Compensatory mutations do not cause drug resistance but instead ameliorate costs associated with 
particular resistance-encoding mutations (Zur Wiesch et al. 2011). In M. tuberculosis, mutations in 
ahpC and rpoA/rpoC have been implicated in compensation of fitness defects associated with INH 
and RIF resistance, respectively (Sherman et al. 1996; Comas et al. 2012). Once a compensatory 
mutation has been acquired, positive epistasis between the resistance-encoding mutation and the 
compensatory mutation ensures that bacteria do not revert to wild-type status, even in the absence 
of drug selective pressure (Andersson and Hughes, 2010). In support of its epistatic involvement, 
studies have shown that the introduction of compensatory mutations into wild-type strains lacking 
corresponding resistance-encoding mutations, undergo fitness costs (Schrag et al. 1997; Trindade et 
al. 2009; Shcherbakov et al. 2010). The complex interplay between drug resistance-encoding 
mutations, compensatory mutations and strain genetic background warrants further research, 
particularly within the context of outbreak and other clinical strains. 
 
1.2.3.1  Drug resistance-conferring mutations and fitness costs 
The acquisition of resistance-encoding mutations in the absence of drugs is often associated with a 
biological fitness cost. Using laboratory-derived strains, several studies have provided significant 
insights into the fitness of bacteria harbouring drug resistance. Pym et al (2002) used isogenic 
strains to show that the S315T katG mutation is associated with the lowest fitness cost and is 
important for retaining virulence in INH-resistant mutants. Similarly, isogenic rpoB mutants were 
shown to undergo differential fitness costs depending on the type of resistance-encoding mutation, 
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with the S531L mutation being the most beneficial and the R529Q mutation posing the greatest cost 
(Gagneux et al. 2006). This study also demonstrated the importance of strain genetic background in 
the relative fitness of mutant strains. A landmark study later revealed the presence of compensatory 
mutations in RNA polymerase genes which improve overall fitness costs associated with RIF-
resistance mutations (Comas et al. 2012). In subsequent studies, WGS detected rpoA and rpoC 
mutations in transmissible strains from various geographic locations, supporting the biological 
relevance of these fitness-compensatory mutations in M. tuberculosis isolates (de Vos et al. 2013; 
Casali et al. 2014; Cohen et al. 2015). Taken together, the most frequent resistance-conferring 
mutations in clinical isolates are believed to have low- or no- fitness cost. In the case of less 
frequently-occurring mutations, compensatory mutations assist in the amelioration of fitness costs. 
Figure 1.2 summarises the impact of fitness on the evolution of drug resistance (Müller et al. 2013).  
 
Despite isogenic strains being practical and ‘genetically controlled’ (Brandis and Hughes, 2013) 
clinical strains are advantageous in that they 1) closely mimic the virulent nature of M. tuberculosis 
strains and 2) highlight the importance of genetic background in experimental fitness studies 
(Coscolla and Gagneux, 2011). In a pilot study by Davies et al. (2000), patient isolates which 
belonged to a single strain differed in fitness, with the drug-resistant isolate undergoing a 
physiological cost relative to the susceptible isolate. In contrast, a study utilising serial patient 
isolates of various lineages, demonstrated that the acquisition of drug resistance did not incur 
significant fitness costs – a finding related to low fitness costs associated with katG, inhA and rpoB 
mutations (Bhatter et al. 2013). Heterogeneity of drug resistance thus emphasizes the need for more 










Figure 1.2 The influence of Darwinian fitness on the emergence of multidrug-resistant (MDR-) and 
extensively drug-resistant (XDR-) tuberculosis (TB). Higher and lower fitness levels of bacteria are 
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indicated by small blue or red circles, respectively. Yellow and red arrows and ovals indicate low-
cost and high-cost resistance mutations, respectively. Blue arrows and ovals indicate compensatory 
mutations. Black arrows refer to baseline genomic characteristics of a particular strain genetic 
background. Abbreviation: INH, isoniazid (Müller et al. 2013) 
 
1.2.3.2 Competitive costs of drug resistance 
Simultaneous infections have been reported in individuals, in which two different strains co-exist in 
the same individual (van Rie et al. 2005). While this may not be a problem in low-incidence 
regions, TB patients from high-incidence settings e.g. South Africa, frequently present with 
multiple M. tuberculosis strains in the same sputum sample, albeit in different proportions (Warren 
et al. 2004). This phenomenon may be explained by two mechanisms related to the presence or 
absence of drugs, respectively: 1) during treatment with first-line drugs, susceptible populations are 
reduced, thereby permitting the growth of MDR populations and 2) following the subsequent 
removal of drug pressure (i.e. patient non-compliance or treatment completion), susceptible 
populations re-emerge and ‘overgrow’ due to differences in relative fitness (van Rie et al. 2005). 
Competitive in vitro assays comparing the fitness of resistant and susceptible isolates have revealed 
heterogeneity based on the mutations they harbour i.e. while some mutations may hamper growth 
and survival under oxidative stress; others may have negligible effects (Cohen and Murray, 2004).  
 
1.2.3.3 Virulence and immunogenicity  
Although fitness costs refer to reduced growth rates within a controlled environment, these costs 
can be extended to reduced transmissibility and decreased virulence of M. tuberculosis strains in 
model organisms (Andersson and Hughes, 2007). Given the centrality of macrophages in replication 
and survival of M. tuberculosis, extensive studies have interrogated M. tuberculosis-macrophage 
interactions as a means of understanding immunological, genetic and physiological determinants 
during in vivo infection (Schnappinger et al. 2003; Rengarajan et al. 2005; Giacomini et al. 2001). 
Several studies have used macrophage models to assess intracellular fitness of drug-resistant 
bacteria. Mariam et al. (2004) measured the independent and competitive fitness of 3 spontaneous 
RIF-resistant mutants in an U937 macrophage cell line, and showed decreased fitness compared 
with the parental strain. Similarly, Rey-Jurado et al. (2011) assessed the fitness katG S315T mutant 
and MDR isolates in J774.2 murine macrophages, and demonstrated reduced fitness relative to 
susceptible isolates. In an interesting study with respiratory and extrarespiratory strains, the latter 
was shown to have higher infectivity in human monocyte-derived macrophages (and mice), 
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highlighting the significance of infectivity as an indicator of extrapulmonary dissemination (de 
Viedma et al. 2005).  
 
The immunogenicity of M. tuberculosis strains has been shown to regulate the outcome of infection 
in animal and human studies (Cooper and Khader, 2008; Kaufmann, 2002) with IFN-γ, TNF-α and 
IL-12 being essential factors in the control of infection (Flynn et al. 1993; Flynn et al, 1995; Cooper 
et al. 2011). Manca et al. 1999 compared the growth of clinical isolate CDC1551 to two laboratory 
strains, H37Rv and Erdman, and two clinical isolates, HN878 and HN60. CDC1551-infected mice 
survived longer than those infected with other strains. This was attributed to higher and quicker 
cytokine mRNA expression levels in response to CDC1551 and subsequent stabilisation of chronic 
infection with constant CFU counts. Thus, CDC1551 was found to be more immunogenic, rather 
than more virulent than other M. tuberculosis strains.  
 
A later study by Barczak et al. (2005) looked at immune responses during dual infection with 
varying starting proportions of CDC1551 (hyperimmunogenic and hypovirulent) and W-Beijing 
isolate HN878 (hypoimmunogenic and hypervirulent). In all proportional comparisons, HN878 
presented as the predominant strain indicating a growth advantage. Additionally, all groups 
containing HN878 progressed to death significantly faster than mice infected with CDC1551 alone. 
Interestingly, both strains had similar growth rates in liquid media, suggesting that the observations 
under in vivo condition were not due to differences in fitness. Similarly, increased in vitro fitness of 
drug-resistant F15/LAM4/KZN strains (Naidoo and Pillay, 2014) does not necessitate increased 
virulence as shown in a recent study (Smith et al. 2014). Their study showed decreasing virulence in 
increasingly drug-resistant strains (susceptible > MDR >XDR) however, it should be mentioned 
that all strains were virulent enough to kill SCID mice and exhibited high levels of necrosis relative 
to the Erdman strain (Smith et al. 2014). These findings were similar to earlier studies in guinea 
pigs models which demonstrated decreasing virulence in increasingly INH-resistant M. tuberculosis 
strains (Middlebrook and Cohn, 1953; Mitchison, 1954). 
 
While it may not be clear how accurately in vitro findings correlate to in vivo conditions, laboratory 
studies can still reveal important information regarding resistance and fitness-compensatory 
mutations that may be conferred in the natural environment (Bjorkman and Andersson, 2000). 
Further research using clinical strains may improve our understanding of strain-specific differences 




The enhanced fitness of specific M. tuberculosis genotypes is associated with the presence of 
beneficial drug resistance-conferring mutations and/or compensatory mutations.  
 
1.2.5 Research aim 
The overall aim of this study was to determine the biological fitness of F15/LAM4/KZN, Beijing, 
F11 and F28 clinical strains and correlate these findings with genotypic data. 
 
1.2.6 Objectives 
i. To determine the laboratory fitness of clinical M. tuberculosis strains using in vitro growth, 
viability and competition assays. 
ii. To correlate mutations in common drug resistance-conferring genes i.e. katG, inhA, ahpC, 
rpoA, rpoB, rpoC, gyrA and rrs with fitness.  
iii. To elucidate the mutational profiles of selected clinical strains by WGS and correlate with 
biological fitness. 
iv. To determine the virulence of clinical strains, as surrogates of fitness, by measuring uptake, 
intracellular replication and cytokine responses in THP-1 macrophages 
v. To ascertain whether relapse isolates undergo fitness costs relative to initial isolates, 
following passage in HIV-positive individuals with TB recurrence after successful 
treatment.  
 
1.2.7 Scope of thesis 
This thesis comprises six chapters and is presented in a “thesis by manuscript” format. The first 
chapter includes the introduction and literature review. In Chapter two, the fitness of clinical strains 
is elucidated using various in vitro assays and correlated with mutations in common drug resistance-
encoding genes. Using a WGS approach, the mutational profiles of selected clinical strains are 
examined in Chapter three, with particular focus on drug resistance and fitness-compensatory 
mutations. Chapter four addresses the virulence properties of clinical strains in a THP-1 
macrophage model, in terms of uptake efficiencies, growth indices and multi-cytokine responses. In 
Chapter five, the fitness of paired isolates is explored as a putative contributor to relapse in HIV-
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The role of fitness in transmission of drug-resistant strains has been explored in previous studies; 
but has not been established for F15/LAM4/KZN strains, which were responsible for the 
extensively drug-resistant tuberculosis (XDR-TB) outbreak in Tugela Ferry, South Africa. The 
biological fitness of 15 clinical strains representing the F15/LAM4/KZN, Beijing, F11 and F28 
families was determined by growth, viability and competition assays and correlated with DNA 
sequencing of eight genes associated with drug resistance and putative compensatory mechanisms. 
Similar growth rates were observed among susceptible, multidrug-resistant (MDR) and XDR strains 
of the KZN and F28 genotypes. In contrast, Beijing and F11 MDR strains demonstrated 
significantly reduced fitness. Resistant strains exhibited heterogeneous fitness profiles in 
competition with different susceptible strains, suggesting strain dependence. In addition, co-culture 
growth rates were consistently higher than independent growth rates in 13/14 competition pairs. All 
14 drug-resistant strains retained viability, at a low CFU/mL, when paired with susceptible strains. 
The persistence of such resistant strains could consequently support the acquisition of additional 
drug-resistance-conferring mutations and/or the evolution of compensatory mechanisms. Frequently 
occurring mutations were detected in KZN and F28 resistant strains whereas, the Beijing MDR 
strain harboured a less common katG mutation and the F11 MDR strain had no katG mutation. 
Contrary to drug-resistant Beijing and F11 strains, the successful transmission of KZN strains, 
particularly during the outbreak, may be attributed to the presence of drug-resistance-conferring 
mutations associated with little or no associated fitness costs. Amplified growth in co-culture may 
be suggestive of in vivo trans-complementation. 
 
INTRODUCTION 
Multidrug-resistant tuberculosis (MDR-TB) represented 3.7 % of new cases and 20 % of previously 
treated cases worldwide. An alarming 9 % of the average fraction of all these cases were 
extensively drug-resistant (XDR) -TB [1]. South Africa, which is ranked number 1 of 22 high TB-
burdened countries globally, reported 1.8 % of new TB cases and 6.7 % of previously treated TB 
cases as MDR-TB [1]. Of these, 10 % were XDR-TB, which is among the highest globally [2].  
 
Mathematical models have predicted the successful spread of drug-resistant Mycobacterium 
tuberculosis strains to be dependent on strain fitness [3]. The fitness of a pathogen is dependent on 
the rates at which drug-susceptible and drug-resistant cell populations compete in an infected 
organism and the environment, are transmitted between organisms, and are eliminated from infected 
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organisms [4]. The magnitude of these factors is variable depending on the degree and pattern of 
antibiotic usage [4]. Drug-resistant strains often demonstrate decreased competitive ability against 
susceptible strains in the absence of the drug [5]. This fitness ‘cost’ is dependent on strain genetic 
background and specific drug-resistance-conferring mutations, which can be improved by 
compensatory evolution [6].  
 
The F15/LAM4/KZN genotype, first detected in the province of KwaZulu-Natal in the mid-1990s, 
was largely associated with drug resistance [7]. The emergence of the MDR forms of this genotype 
during the same period coincided with increasing HIV prevalence rates and limited access to 
antiretroviral treatment [7]. Second-line resistance began to emerge between 1997 and 2000, 
followed by the isolation of the first XDR strain in 2001, preceding the outbreak of the XDR-
F15/LAM4/KZN strains in Tugela Ferry in 2005 [8].  
 
Between 2004 and 2005, the Beijing genotype accounted for 11 % of MDR strains; the F11 
genotype for 7 % of all MDR and 10 % of pre-XDR and XDR strains; and the F28 genotype 
represented the highest proportion (49 %) among the MDR, 30 % of pre-XDR and 9 % of the XDR 
strains in KwaZulu-Natal (M. Pillay, personal communication).  
 
Both MDR and XDR strains of F15/LAM4/KZN, F11 and F28 are transmitted regardless of fitness 
costs believed to be associated with drug-resistance-conferring mutations [9]. In this study, we 
explore for the first time, the fitness of the F15/LAM4/KZN, F11 and F28 families, compared with 
the Beijing family, which has been previously extensively characterized [10]. Although it is not 
clear how accurately in vitro findings correlate to in vivo conditions, laboratory data can elucidate 
important information regarding resistance, fitness and compensatory mutations that may be 
conferred in the natural environment [11]. The overrepresentation of specific genotype families 
among cases of drug resistance and the subsequent successful transmission of these strains are of 
paramount importance in relation to TB control regimens [12]. 
 
METHODS AND MATERIALS 
 
M. tuberculosis isolates 
The genotypes and the respective drug-resistance profiles of the 15 clinical isolates included in this 
study are listed in Table 2.1. Genotypes of the isolates were determined by spoligotyping in 
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previous studies as per the manufacturer’s instructions (Isogen Bioscience B.V., Hyderabad, AP, 
India). Drug susceptibility was determined using the 1% agar proportion method [13]. 
 
Table 2.1 Genotype and drug susceptibility of clinical strains used in the study 
I: Isoniazid; R: Rifampicin; S: Streptomycin; E: Ethambutol; O: Ofloxacin; K: Kanamycin; C: Capreomycin;  
N: Niacinamide, MDR: multidrug-resistant; XDR: extensively drug-resistant 
 
Preparation of M. tuberculosis inoculum 
Frozen stocks were prepared by inoculating 100 µL of each strain into Middlebrook 7H9 broth (20 
mL supplemented with 10 % oleic albumin dextrose catalase (OADC), 0.05 % Tween-80 and 0.5 % 
glycerol). After aerobic incubation at 37 °C, with agitation, aliquots of 1000 µL were frozen once 
an optical density at 600 nm (OD600) of 0.9–1.2 was reached. For the growth and competition 
assays, frozen stocks were inoculated into 100 mL of Middlebrook 7H9 broth in triplicate, 
incubated with agitation at 37°C until an OD600 of 1.6–1.8 was reached. After centrifugation at 1780 
g at 4 °C for 10 min, the pellet was washed twice with PBS containing 0.05 % Tween-80 and re-




Genotype family Drug resistance 
profile 
Type 
V9124 21-24, 33-36, 40 60 F15/LAM4/KZN None Susceptible 
V4207 21-24, 33-36, 40 60 F15/LAM4/KZN None Susceptible 
V1435 21-24, 33-36, 40 60 F15/LAM4/KZN IRS MDR 
V2475 21-24, 33-36, 40 60 F15/LAM4/KZN IR MDR 
KZN605 21-24, 33-36, 40 60 F15/LAM4/KZN IRSEOKCN XDR 
X162 21-24, 33-36, 40 60 F15/LAM4/KZN IRSEOKCN XDR 
B910 1-34 1 Beijing None Susceptible 
B1528 1-34 1 Beijing None Susceptible 
R35 1-34 1 Beijing IRS MDR 
R283 1-34 1 Beijing IR MDR 
R490 9-11, 21-24, 33-36 33 F11 None Susceptible 
R271 9-11, 21-24, 33-36 33 F11 IR MDR 
R104 9, 10, 33-36 34 F28 None Susceptible 
R443 9, 10, 33-36 34 F28 IRON MDR 
R262 9, 10, 33-36 34 F28 IRSEOKCN XDR 
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suspended in 1 mL of Middlebrook 7H9 broth. Homogeneous suspensions were obtained by 
vigorous pipetting. 
 
Fitness of axenic cultures 
Re-suspended cultures were back-diluted, in triplicate, in 25 mL of Middlebrook 7H9 broth, to an 
OD600 of 0.015 using the following formula: total OD units X (amount to back-dilute) = (0.015) X 
(25 mL). The CFU/mL corresponding to OD600 0.015 ranged from 3.65E + 05 to 3.10E + 06 for all 
strains (Table S2.1). Cultures were incubated aerobically with shaking at 37°C for 24 days.  
 
Growth and metabolic activity were measured at 4-day intervals for 24 days. In addition, OD600 
measurements were taken at 0, 24, 48 and 70 h during the lag phase. To ensure reproducibility and 
accuracy, all measurements were recorded in triplicate for each of the three biological replicates. 
The CFUs were quantified in triplicate on Middlebrook 7H11 agar (containing 10 % OADC, 0.05 % 
Tween-80 and 0.5 % glycerol) after performing a ten-fold dilution series with PBS (containing 0.05 
% Tween-80). For each strain family, the resistant strains were compared with the susceptible 
strains by a comparison of fitness (W) [14].  
 
 W = ln (R final ÷ Rinitial) / ln (S final ÷ Sinitial) 
 
Where ln represents the natural logarithm and R and S represent the CFU/ml of the resistant and 
susceptible strains, respectively.  The fitness of the drug susceptible strain represented 1. Therefore, 
if W < 1, then the resistant strain encountered a fitness cost, and if W > 1, then it was regarded as fit. 
 
Alamar Blue assay 
Alamar Blue (Life Technologies, Fairland, Roosevelt Park, South Africa) (10 µl) was added to 100 
µl of culture in triplicate a clear 96-well microtitre plate. Broth and Alamar blue alone served as 
negative controls and H37Rv and the reagent represented the positive control. After aerobic 
incubation overnight at 37 °C, a colour change from blue to pink was indicative of metabolically 
active cells. The absorbance was measured at 600 nm in the GloMax system (Promega Corp. 
Madison, WI. USA), using Alamar Blue and broth as a blank. 
 
Pairwise Competition 
Cultures were back-diluted in duplicate into 30 ml of broth. Thereafter, 10 ml each of a drug-
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susceptible and resistant culture were transferred into a 30 ml inkwell bottle, resulting in a total of 
20 ml each of mixed and single cultures. OD600 and CFU counts were performed, in triplicate, at 6-
day intervals for 30 days on the aerobically agitated cultures at 37 °C.  
 
Counts of CFU were quantified in triplicate on Middlebrook 7H10 agar (containing 10 % OADC, 
0.05 % Tween-80 and 0.5 % glycerol) with and without antibiotics. Plates containing isoniazid (1 
mg/L) and rifampicin (1 mg/L) were used to test MDR isolates [13]. In addition, to these 
antibiotics, XDR isolates were inoculated onto agar plates containing kanamycin (5 mg/L) and 
ofloxacin (2 mg/L) [15].  
 
After 21 - 25 days of aerobic incubation at 37 °C, the number of drug-resistant colonies (R) was 
counted on the antibiotic plates. The number of drug-susceptible colonies (S) was enumerated as the 
difference between the number of colonies on the non-antibiotic and antibiotic plates. These colony 
counts were then used to quantify the CFU/ml used to calculate the mean competitive relative 
fitness index (W) for each drug-resistant strain. 
 
PCR amplification 
A total of three susceptible, four MDR, and three XDR clinical isolates was examined for drug 
resistance-conferring and compensatory mutations by DNA sequencing. DNA was isolated as 
previously described [15]. The primers listed in Table 2.2 were used to amplify the following target 
genes: katG, inhA, ahpC, rpoA, rpoB, rpoC, gyrA and rrs. PCR was performed in a 25-µl mixture 
consisting of 0.25 mM dNTPs, each primer (0.25 µM), 0.5 U of EconoTaq Polymerase (Lucigen), 1 
x PCR buffer and 5 µl of template DNA. H37Rv was used as the positive control and nuclease-free 
water as the negative control. The thermal cycling conditions included denaturation at 95 °C for 10 
min, followed by 40 cycles at 95 °C for 20 s, 55°C for 1 min and 72°C for 30 s and a final extension 
at 72 °C for 5 min. PCR products were visualized in 1.5 % agarose gels containing ethidium 









Table 2.2 Primer pairs and sequencing primer used for PCR amplification and DNA sequencing 
Locus Nucleotide sequence (5’ – 3’) Product size (base pairs) Reference 
katGF GCAGATGGGGCTGATCTACG  Zenteno-Cuevas et al. (2009) 
katGR AACTCGTCGGCCAATTCCTC 580 Zenteno-Cuevas et al. (2009) 
inhAF TGCAATTTATCCCAGCGAAG  Primer 3 (v 0.4.0) 
inhAR ACCGAAATGCAGGTAGTGCT 886 Primer 3 (v 0.4.0) 
ahpCF GCGATGCCGATAAATATGGT  Primer 3 (v 0.4.0) 
ahpCR ATACCTGCGGATTTCGTGTC 877 Primer 3 (v 0.4.0) 
rpoAF GAGTACTACTCAAAGTAAACCC  Comas et al. (2012) 
rpoAR CTTCTGATGTGAAGACGACC 1239 Comas et al. (2012) 
rpoA AACAACTCGACCAGCGTCTT Sequencing primer Comas et al. (2012) 
rpoBF TGGTCCGCTTGCACGAGGGTC  van der Zanden et al. (2003) 
rpoBR CTCAGGGGTTTCGATCGGGCA 437 van der Zanden et al. (2003) 
rpoCF TCCGACTTGAACGACCTGTA  Comas et al. (2012) 
rpoCR GTTGCGCTCGTCGTGGTTCA 1298 Comas et al. (2012) 
gyrAF CAGCTACATCGACTATGCGA  Takiff et al. (1994) 
gyrAR GGGCTCGGTGTACCTCAT 320 Takiff et al. (1994) 
rrs1F AAGGGCTGCGATGCCGCGAG  Primer 3 (v 0.4.0) 
rrs1R AAGTCCGAGTGTTGCCTCAGG 433 Primer 3 (v 0.4.0) 
rrs2F AGGTGTGGGTTTCCTTCCTT  Primer 3 (v 0.4.0) 
rrs2R CGTTGCTGATCTGCGATTAC 540 Primer 3 (v 0.4.0) 
rrs3F CTGAGATACGGCCCAGACTC  Primer 3 (v 0.4.0) 
rrs3R TAAGGTTCTTCGCGTTGCATC 656 Primer 3 (v 0.4.0) 
rrs4F GTGGCCGTTTGTTTTGTCAG  Primer 3 (v 0.4.0) 
rrs4R TGCAATATTCCCCACTGC 437 Primer 3 (v 0.4.0) 
F: forward primer; R: reverse primer 
 
DNA Sequencing  
Purification and sequencing of the PCR products were performed by Inqaba Biotec using the PCR 
forward primers, with the exception of the rpoA gene for which a sequencing primer was 
synthesised (Table 2.2). Termination reactions were performed using BigDye® Terminator v3.1 
(ABI, Life Technologies). The labelled fragments were purified using the Zymo Research 
Sequencing Clean-up Kit and subsequently analysed in a 3500XL Genetic Analyzer (ABI, Life 
Technologies). Multiple sequence alignment was performed using BioEdit software. Due to the re-
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All statistical analysis was performed using SPSS software version 19.0 (IBM). One-way Repeated 
Measures ANOVA was used for multiple comparisons of the Mean ± SD obtained in the lag phase, 





OD assay  
No significant differences were found among any of the resistant strains compared with susceptible 
ones during the lag phase of growth (data not shown). Relatively similar growth was observed 
among susceptible, MDR and XDR-F15/LAM4/KZN strains (Figure S2.1). However, both Beijing 
MDR strains (R35 and R283) presented with a lower OD than the susceptible strains (B910 and 
B1528). This was significantly different between R35 and B910 (p=0.016), R283 and B910 
(p=0.022) and R35 and R283 (p=0.046). Similarly, susceptible (S) strains F11-R490 and F28-R104 




In comparison to H37Rv, fitness of three of the four F15/LAM4/KZN drug-resistant strains was 
reduced (Table S2.2). X162 (XDR) displayed increased fitness compared with both susceptible and 
reference strains, whereas KZN605 (XDR) was the least fit of the drug-resistant strains in all three 
comparisons. V1435 (MDR) was only less fit than H37Rv. V2475 (MDR) and KZN605 were 
significantly less fit than X162 relative to V4207 (S) (p=0.017 and p=0.012, respectively) and 
H37Rv (p=0.012 and p=0.008, respectively).  
 
Beijing-R35 (MDR) was less fit than Beijing-B1528 (S) and H37Rv but not B910 (S). Beijing-R283 
(MDR), however, was fitter than all three susceptible strains. No significant differences were found 
between any of these comparisons. 
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F11-R271 (MDR) presented with fitness costs compared with F11-R490 and reference strain 
H37Rv. F28-R443 (MDR) was marginally less fit than R104 (S), but not less fit than H37Rv, 
whereas F28-R262 (XDR) was less fit than both. 
 
Alamar Blue assay  
The Alamar Blue assay (Figure S2.2) showed similar metabolic activity for the F15/LAM4/KZN 
strains, with significant differences in viability only between V4207 (S) and V2475 (MDR) 
(p=0.022). Among the Beijing family, the viability of MDR strain R283 was significantly reduced 
compared with both susceptible strains, B910 (p=0.026) and B1528 (p=0.030). R35 (MDR) showed 
significantly lower fitness than B910 (p=0.021) and B1528 (p=0.021). Similar to the OD assay, the 
F11 strain R271 (MDR) displayed significantly reduced viability compared with R490 (S) 
(p=0.004). Among the F28 family, although R104 (S) grew at a consistently higher rate than R443 
(MDR), it did not reach significance. R262 (XDR) displayed increased fitness after day 12, with the 
exception of day 20, which suggests a pipetting error. 
 
Competitive growth 
In pairwise competition experiments, similar trends were observed in the OD and CFU assays 
(Figure 2.1), whereby the susceptible strain exhibited significantly higher growth (Table S2.3; 
Figures S2.3-2.8) than its resistant counterpart throughout the experimental period. The exception 
was the KZN-X162 (XDR), whose growth had surpassed that of both the susceptible strains by day 
30 of the OD assay, but this was not statistically significant. The growth of this strain was almost 
identical to KZN-V9124 (S) until day18 (Figure 2.1D) but lower than that of KZN-V4207 (S) in the 






















Figure 2.1 Optical density (OD) measurements and colony forming units (CFU) counts for 
competitive KZN strain pairs. (A) OD values and (B) CFU/ml for V9124 (S) + V1435 (MDR). (C) 
OD values and (D) CFU/ml for V9124 (S) + X162 (XDR). Data is represented as the mean ± SD of 
duplicate experiments. S: susceptible; MDR: multidrug-resistant; XDR: extensively drug-resistant. 
 
Optical density values for co-culture were consistently higher than those of independent cultures 
(Figure 2.1A, 2.1C Figures S2.3 –S2.5) with the exception of the Beijing pair, B1528 (S) + R283 








All the KZN MDR, three of the four Beijing MDR and the F11 MDR pairs experienced fitness costs 
in competition with susceptible strains (Figure 2.2). In contrast, both KZN XDR strains were fit. 
The F28 XDR strain exhibited a minimal competitive cost paired with R104 (S). Higher fitness 
indices were observed for all KZN MDR and XDR strains when paired with V9124 (S) compared 
with V4207 (S), and for Beijing-resistant strains when paired with B1528 (S) compared with B910 
(S). This difference was statistically significant between the KZN605 (XDR) pairs (p=0.017). 
Furthermore, R283 (MDR) (paired with B1528) was the fittest strain among the four genotype 





















Figure 2.2 Mean competitive relative fitness for KZN, Beijing, F11 and F28 drug-resistant strains. 
The fitness index of the susceptible strain is taken as 1 (solid black line). Fitness indices below 1 
indicate fitness costs and fitness indices above 1 indicate no loss of fitness. The data above is 





Eight genes associated with drug resistance were sequenced in eleven clinical strains and H37Rv on 
day 12 of the growth assays. Multiple sequence alignment with H37Rv in Tuberculist showed no 
differences between both reference strains. Sequencing detected four different mutations in rpoB, 
two in gyrA and katG, one in rpoC and rrs, and none in rpoA, inhA or ahpC (Table 2.3). Identical 
mutations were present in both KZN and the F28 XDR strains: double mutations 
Asp516Gly/Leu533Pro in rpoB and Ala90Val/ Ser95Thr in gyrA, and single mutations Ser315Thr 
in katG, A1402G in rrs and Ala542Ala in rpoC. Different rpoB mutations were harboured in the 
three MDR strains belonging to the different families. However, Ser531Leu in rpoB was common 
to both MDR F11 and Pre-XDR F28. All drug-resistant KZN and F28 harboured Ser315Thr, 
whereas Beijing harboured Ser315Asn in katG. Ser95Thr in gyrA was present in all sensitive 

















Table 2.3 Distribution of nonsynonymous and synonymous mutations in selected clinical strains 




Strain Genotype family Resistance 
profile 
rpoA rpoB rpoC katG inhA ahpC gyrA rrs 
V9124 F15/LAM4/KZN None - - Ala542Ala - - - Ser95Thr - 
V2475 F15/LAM4/KZN IR - Asp516Thr Ala542Ala Ser315Thr - - Ser95Thr - 
KZN605 F15/LAM4/KZN IRSEOKCN - Asp516Gly 
Leu533Pro 
Ala542Ala Ser315Thr - - Ser95Thr 
Ala90Val 
A1402G 
X162 F15/LAM4/KZN IRSEOKCN - Asp516Gly 
Leu533Pro 
Ala542Ala Ser315Thr - - Ser95Thr 
Ala90Val 
A1402G 
B910 Beijing None - - - - - - Ser95Thr - 
R35 Beijing IRS - Leu533Pro - Ser315Asn - - Ser95Thr - 
R490 F11 None - - Ala542Ala - - - Ser95Thr C492T 
R271 F11 IR - Ser531Leu Ala542Ala - - - Ser95Thr C492T 
R104 F28 None - - - - - - Ser95Thr - 
R443 Beijing IRSEK - Ser531Leu - Ser315Thr - - Ser95Thr - 
R262 Beijing IRSEOKCN - Asp516Gly 
Leu533Pro 
Ala542Ala Ser315Thr - - Ser95Thr 
Ala90Val 
A1402G 




From an epidemiological perspective, the principal dynamic that impacts the spread of drug-
resistant strains is the fitness cost associated with the resistance mutations they harbour [17]. In our 
study, MDR and XDR strains representing the F15/LAM4/KZN and F28 genotypes demonstrated 
enhanced fitness despite the burden of carrying drug-resistance-conferring mutations. In contrast, 
Beijing and F11 MDR strains exhibited significantly reduced fitness.  
 
All the F15/LAM4/KZN, Beijing and F28 resistant strains had a fitness index above 0.7 in the CFU 
growth and competition assays, with the exception of KZN605 and V2475, which had fitness 
indices of 0.61 and 0.65, respectively, in competition with V4207. Hypothetically, co-infection with 
V4207 may impede the successful spread of these two resistant strains to other hosts, unless 
selected for by antibiotic pressure. The mean fitness of 0.44 ± 0.13 of F11-R271 (MDR) in pairwise 
competition is hardly surprising, given its reduced growth in axenic cultures (Figures S2.1 and 
S2.2). Therefore, this strain would not be expected to spread successfully in the population. 
 
Pairwise competition revealed three generalized patterns of growth. First, there was an ‘overgrowth’ 
of susceptible strains in the CFU results obtained, most likely attributable to differences in fitness 
between co-infecting susceptible and resistant strains [10, 18]. However, all 14 drug-resistant strains 
retained viability, at a low CFU/mL, when paired with susceptible strains. The persistence of such 
resistant strains could consequently support the acquisition of additional drug resistance-conferring 
mutations and/or the evolution of compensatory mechanisms.  
 
Second, fitness profiles of the F15/LAM4/KZN and Beijing resistant strains during competition 
were heterogeneous, i.e. all the former strains had higher fitness paired with KZN-V9124 (S) 
compared with KZN-V4207 (S), with significant differences between both KZN605 (XDR) pairs 
(p=0.022). Similarly, the Beijing MDR strains had higher fitness with B910 (S) compared to B1528 
(S). This is most likely due to fitness differences between susceptible strains. Together, the results 
are suggestive of strain dependence. Lastly, growth in co-culture was amplified compared with 
single cultures in 13 of 14 competition pairs. To the best of our knowledge, this phenomenon in co-
culture noted after 2 weeks of growth, has not been reported in M. tuberculosis before. We 
hypothesise that one strain may be promoting or suppressing the growth of the other by means of a 
putative growth factor, or other signalling molecules. In contrast, Bhatter et al. [14] recently showed 
mutual inhibition of growth of susceptible and resistant strains from the MANU genotype during a 
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competition assay. Hence, differences in competitive behaviour may be a reflection of biological 
differences between strain genotypes. 
 
The high frequency of Ser315Thr katG mutations in clinical isolates in our study illustrate its 
importance in conserving catalase/peroxidase activity, virulence and reduced conversion of 
isoniazid into active form, while maintaining mycobacterial fitness [19]. The Beijing MDR strain, 
however, harboured a different mutation (Ser315Asn) in katG. This mutation, although associated 
with a small reduction (4%) in virulence, presented with significantly reduced catalase–peroxidase 
activity compared with four other katG mutants, including the Ser315Thr mutant, in a study by 
Unissa et al. [20]. The presence of the Ser315Asn mutation could consequently explain the reduced 
fitness of Beijing-R35 (MDR) in all the assays. 
 
All seven resistant strains harboured mutations in the sequenced 81-bp hot-spot region of rpoB that 
accounts for >95% of rifampicin resistance in clinical M. tuberculosis strains [21]. The XDR strains 
harboured a common mutation (Asp516Gly) that was distinguishable from the MDR 
F15/LAM4/KZN strain (Asp516Tyr). This supports the findings of others that propose independent 
acquisition of rpoB mutations for MDR and XDR F15/LAM4/KZN strains [22]. In addition to 
Asp516Gly, the XDR strains possessed a second rpoB mutation at codon 533, identical to the 
mutation present in the Beijing MDR strain. 
 
The F11 and F28 MDR strains possessed the most frequently occurring rifampicin resistance-
conferring mutation, Ser531Leu associated with minimal or no fitness loss in clinical isolates [21, 
23]. Taken together with the Ser315Thr mutation in katG, the increased fitness of F28-R443 (MDR) 
in the OD, Alamar Blue and CFU assays can be attributed to its predisposition to ‘beneficial’ fitness 
mutations in rpoB and katG. Despite the presence of Ser531Leu in F11-R271 (MDR), it grew 
poorly in comparison to the susceptible strain in the growth and competition assays. The reduced 
fitness of this strain may be attributed to an unidentified katG mutation that it may harbour, which 
may be slowing down its growth despite the beneficial rpoB mutation it possesses.  
 
No mutations were detected in the inhA sequenced region in any of the isolates. Mutations have 
been reported in the inhA promoter region for KZN-V2475 (MDR) and another F15/LAM4/KZN 
XDR strain, KZN-R506 [22]. However, we had not sequenced this region because of financial 
constraints. No putative compensatory mutations were detected in the ahpC, rpoA or rpoC genes for 
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any clinical strain. However, there could be other mechanisms of compensation for which whole 
genome sequencing could provide more insight. The presence of synonymous mutation Ala542Ala 
in rpoC for F15/LAM4/KZN strains, F11 strains and F28-R262 (XDR) is in accordance with a 
recent study that demonstrated this mutation in Lineage 4 strains only [24]. A natural 
polymorphism, thought to be unassociated with fluoroquinolone susceptibility [25], was observed at 
codon 95 of gyrA in all 11 clinical strains. In addition, both resistant and susceptible F11 strains 
possessed the C492T polymorphism in rrs, which is useful as a phylogenetic marker for such strains 
[26].  
 
Identical mutations were detected in katG (Ser315Thr), rpoB (Asp516Gly, Leu533Pro), rpoC 
(Ala542Ala), gyrA (Ala90Val, Ser95Thr) and rrs (A1402G) for all three XDR strains. This is 
supported by whole genome sequencing of M. tuberculosis XDR strains that revealed only a few 
differences among them [22]. These mutations that confer resistance to first- and second-line drugs 
appear to be favourable to the XDR organisms, as displayed by their unimpeded growth in the 
growth and competition assays of this study. A recent comparison of the XDR strains from the 
Tugela Ferry outbreak to a panel of phylogenetically distinct drug-resistant and susceptible strains 
of M. tuberculosis showed very little substantiation for compensatory mechanisms [27]. This has 
significant implications for the pathogenicity and transmissibility of these strains, which carry 
mutations in several essential genes. The possibility arises that these strains may be more suited to 
compromised populations, including HIV-infected individuals, in which the organism’s minimal 
fitness costs are negligible. 
 
There are a few limitations of this study. First, only co-cultures were plated out and we were 
therefore unable to correlate these findings with axenic susceptible and resistant CFU counts in the 
competition assays. Second, only a limited number of genes and gene regions could be sequenced in 
this study. Therefore, other significant mutations correlating with observed fitness phenotypes may 
have gone undetected.  
 
In conclusion, paired growth of competing resistant and susceptible strains illustrated a slight 
‘additive’ effect in comparison to independent growth. This in vitro finding may be postulated to 
represent an in vivo occurrence with implications in high-incidence TB settings, including South 
Africa, that are burdened with a wide spectrum of strain diversity and drug resistance. Furthermore, 
strains with differing drug-resistance phenotypes [28] and strain genotypes [29] have been found to 
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co-exist in hosts in South Africa. Our findings demonstrate that the successful spread of 
F15/LAM4/KZN strains during the Tugela Ferry XDR-TB outbreak in 2005 may be attributed to 
the presence of drug resistance-conferring mutations associated with little or no fitness cost. This 
conclusion is in agreement with previous observations that drug-resistant F15/LAM4/KZN strains 
are highly transmissible [7] and highlights the importance of TB surveillance systems, which may 
prevent future epidemics caused by fit resistant strains. 
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While the acquisition of drug resistance is often accompanied by fitness costs, Mycobacterium 
tuberculosis has developed mechanisms to overcome these costs in the form of compensatory 
mutations. In an attempt to dissect strain-specific differences in biological fitness, ten M. 
tuberculosis genomes, representing F15/LAM4/KZN, Beijing, F11 and F28 genotypes were 
sequenced on the Illumina MiSeq platform. Drug-susceptible F15/LAM4/KZN strains differed by 
43 SNPs, demonstrating that heterogeneity exists even among closely-related strains. We found 
unique, non-synonymous single nucleotide polymorphisms (SNPs) in the sigA and grcC1 genes of 
MDR and XDR F15/LAM4/KZN strains, respectively. The F28 MDR strain harboured a novel ubiA 
mutation in combination with its embB M306I mutation, which may be related to ethambutol 
resistance. In addition, it possessed a low-frequency rpoC mutation, suggesting that this strain was 
in the process of developing compensation. In contrast, no compensatory mutations were identified 
in Beijing and F11 MDR strains, corroborating its low in vitro fitness. Clinical strains also 
harboured unique SNPs in a number of important genes associated with virulence, highlighting the 
need for future studies which examine the correlation of genetic variations with phenotypic 
diversity. In summary, whole-genome sequencing revealed the presence of fitness-compensatory 
mutations in F15/LAM4/KZN and F28 genotypes which predominate in MDR and XDR forms in 
KwaZulu-Natal, South Africa. 
 
INTRODUCTION 
Since the discovery of the first anti-tuberculosis (TB) drug about 70 years ago, M. tuberculosis has 
progressively evolved from monodrug resistant to multidrug resistant (MDR), extensively drug 
resistant (XDR) and recently, totally drug-resistant (TDR) forms, in various parts of the world 
(WHO, 2014). Anti-TB drugs, which are generally designed to target essential, highly conserved 
genes, may be impeded by chromosomal mutations which alter the target site (Sandgren et al. 
2009). The acquisition of drug resistance is often associated with a fitness ‘cost’ as mutations may 
affect the normal function of target genes, thereby reducing the growth rate of M. tuberculosis 
(Andersson and Levin, 1999; Billington et al. 1999; Gillespie 2002). Moreover, strains carrying 
identical resistance-encoding mutations may differ in their ability to spread from person-to-person, 
demonstrating the significance of strain genetic background in the context of fitness (Gagneux et al. 
2006; Fenner et al. 2012). Compensatory mutations however, may help restore the fitness of drug-




The World Health Organisation (WHO) estimated that 1 out of every 100 people in South Africa 
develops active TB disease every year (WHO, 2014). As a result of poor TB control programmes 
and treatment strategies, M. tuberculosis strains have been found to disseminate in MDR (isoniazid 
and rifampicin resistance) and XDR (MDR in addition to resistance to any fluoroquinolone and at 
least one injectable drug) forms in South Africa (Pillay and Sturm 2007; Victor et al. 2007; Cox et 
al. 2010; WHO, 2014; Cohen et al. 2015). Moreover, the appearance of XDR-TB is strongly 
associated with specific strain genotypes (Muller et al. 2013; Cohen et al. 2015), including the 
F15/LAM4/KZN (KZN) genotype which caused the largest XDR-TB outbreak, in Tugela Ferry, 
KwaZulu-Natal (Gandhi et al. 2006). Our recent study demonstrated increased fitness for KZN 
strains in laboratory culture, contrasting with Beijing and LAM3 MDR strains which were 
characterized by impeded growth and metabolic profiles (Naidoo and Pillay 2014). Competitive 
fitness assays also showed consistently lower fitness indices for most drug-resistant strains, when 
compared with susceptible competitor strains (Naidoo and Pillay 2014). In support of this, 
preliminary sequencing of selected resistance-conferring genes revealed the presence of low or no 
fitness cost mutations in KZN and F28 strains and high fitness cost mutations in Beijing and F11 
strains.  
 
Despite the recent advances in understanding the biological cost of drug resistance, this subject 
remains incompletely studied among clinical strains. This is in part due to the difficulty in assessing 
the effects of strain-specific variation on TB pathogenesis. The introduction of next-generation 
sequencing technology may help decipher the functional and clinical consequences of M. 
tuberculosis genetic diversity, displayed in the form of single nucleotide polymorphisms (SNPs), 
small insertions and deletions (indels) and gene rearrangements (Coscolla and Gagneux 2014). In 
this study, we correlated whole-genome sequencing (WGS) data with previous experimental fitness 
data of ten clinical strains from South Africa. Comparative genomic analysis revealed the existence 
of significant sequence diversity among clinical strains and helped uncover novel mutations - some 












Ten M. tuberculosis strains were selected for WGS analysis. These included four susceptible, four 
MDR and two XDR strains for which drug susceptibility testing was performed previously (Naidoo 
and Pillay 2014). Spoligotyping and IS6110-RFLP typing were performed previously (Naidoo and 
Pillay 2014), classifying strains into four families, namely: F15/LAM4/KZN (n = 4), Beijing (n = 
2), F11/LAM3 (n =2) and F28/S (n = 2). Mycobacteria were grown in Middlebrook 7H9 broth 
(Difco) containing 10% oleic albumin dextrose catalase (OADC) (BD Biosciences), 0.5% glycerol 
(Sigma) and 0.05% Tween-80 (Sigma) at 37 °C, until an optical density (OD600) of 1. 
 
Whole genome sequencing 
Genomic DNA was isolated using the CTAB-lysozyme method (Larsen et al. 2007) and purified 
using the Genomic DNA Clean & Concentrate KitTM (Zymo Research, Pretoria, South Africa). 
Whole-genome sequencing was performed using the Illumina MiSeq Sequencer (Illumina) at 
Inqaba Biotec (Pretoria, South Africa). An Illumina-provided tagmentation kit (Nextera) was used 
for library preparation. Paired-end massively parallel sequencing (2 x 300 bp) was carried out with 
a MiSeq v3 sequencing kit.  
 
Read mapping 
Raw sequence reads were trimmed to remove adaptor sequences and low quality sequences using 
the CLC Genomics Workbench (version 7.5.1; QIAGEN, Aarihus, Denmark). The ‘Map Reads to 
Reference’ function was used to assemble paired reads from all strains to the M. tuberculosis 
H37Rv reference genome (NCBI accession # N000962) using the following parameters: similarity 
fraction = 0.8,  length fraction = 0.5, mismatch cost of 2, deletion cost of 3 and insertion cost of 3. 
Similarly, KZN strains were mapped against KZN-4207 (NCBI accession # CP001662), a 
previously sequenced susceptible strain. In addition, re-sequenced MDR and XDR- KZN strains, 
V1435 and KZN605, were mapped against previous versions by the Broad Institute 
(www.broad.mit.edu/annotation/genome/mycobacterium_tuberculosis_spp) (NCBI accession # 
CP001658 and # NC_018078, respectively). Beijing strains were mapped against HN878 (NCBI 
accession # NZ_CM001043) and F11 strains were mapped against the F11 reference genome 
(NCBI accession # NC_009565). Since no reference genome was available for F28, this sequence 
was mapped against H37Rv only. All statistical information was derived from the resulting table 
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generated by the software. The ‘k-mer based tree construction’ function in the CLC Genomics 
Workbench was used for phylogram construction. Regions with low coverage were filled from the 
reference sequence (H37Rv) and quality scores were used for conflict resolution.    
 
SNP analysis and confirmation 
Drug resistance-conferring mutations were characterised using publicly available databases 
including TBDreaMDB and the Broad Institute Tuberculosis Drug Resistance Mutation Database, 
together with recently published reports. Variants were called on the basis of high quality (Phred 
score of Q30) and more than 70% of the reads reflecting the SNP. SNPs with less than ten reads 
mapping to the reference were excluded from analysis. This included repetitive sequence regions 
which usually map poorly due to high GC content. Verification of a subset of SNPs was 
accomplished by PCR using Q5 High-Fidelity DNA Polymerase (NEB) and primers listed in Table 
S3.1. Sanger sequencing was performed on the ABI 3500XL Genetic Analyzer using forward 
primers. Bioedit software and chromatograms were used to analyse sequences for the presence of 
wild-type or mutant peaks. Non-synonymous SNPs (nSNPs) were categorised into functional 
groups according to Tuberculist (Lew et al. 2011). A selection of genes encoding virulence factors 
was inspected for nSNPs, across the four strain families (Smith, 2003). We used the ‘InDels and 
Structural Variants Tool’ on paired reads mapped to H37Rv with the following parameters: P-value 
threshold = 0.0001, maximum number of mismatches = 2 and minimum number of reads = 2.  
 
Minimum inhibitory concentration (MIC) testing of isoniazid and ethambutol 
Strains were cultured on Middlebrook 7H11 agar (Difco) and adjusted to a McFarland no. 1 
turbidity standard in phosphate buffered saline with Tween-80. Serially-diluted suspensions were 
inoculated onto Middlebrook 7H10 agar containing 10% OADC, 0.5% glycerol and drug 
concentrations ranging from 0.0625 to 16 mg/L for isoniazid (INH) and 0.4687 to 120 mg/L for 
ethambutol (EMB). Strains were classified as having low-level or high-level resistance in the 
presence of 0.2 mg/L or 1 mg/L of INH, respectively. Two critical breakpoints of 5 and 7.5 mg/L 
were tested for EMB. 
 
Ethical approval 
Ethical approval was obtained from the Biomedical Research Ethics Committee, University of 






Whole genome sequencing 
Mapping reports detailing summary statistics of read distribution are described in Table S3.2-S3.3. 
Sequencing reads were deposited into the NCBI database under the accession number 
PRJNA305082. Sequencing depth in strains ranged from 20 to 60 X with average read length of 230 




Figure 3.1 Phylogenetic relationships of clinical strains. The tree was constructed by the neighbour-







Table 3.1 Genotype, drug susceptibility and sequencing statistics of clinical strains of M. tuberculosis 
Strain Missing spacers a Genotype Drug resistance a Type b Read count Average read length (bp) Average depth of coverage 
V9124 21-24, 33-36, 40  F15/LAM4/KZN - DS 925,818 265 55.6 X 
V1435 21-24, 33-36, 40  F15/LAM4/KZN IR MDR 475,657 233 25.1 X 
KZN605 21-24, 33-36, 40  F15/LAM4/KZN IREOKCN XDR 505,153 226 25.8 X 
X162 21-24, 33-36, 40  F15/LAM4/KZN IREOKCN XDR 532,585 235 28.4 X 
B910 1-34  Beijing - DS 458,138 231 24.0 X 
R35 1-34  Beijing IRS MDR 1,021,876 244 56.4 X 
R490 9-11, 21-24, 33-36  F11/LAM3 - DS 719,873 189 30.8 X 
R271 9-11, 21-24, 33-36  F11/LAM3 IR MDR 1,362,298 193 59.6 X 
R104 9-10, 33-36  F28/S - DS 380,439 229 19.7 X 
R443 9-10, 33-34  F28/S IRSEK MDR 389,783 253 20.7X 
a I: isoniazid, R: rifampicin, E: ethambutol, O: ofloxacin, K: kanamycin, C: capreomycin, N: niacinamide, S: streptomycin. 










Mapping of F15/LAM4/KZN strains to KZN-4207 
Sequence reads from KZN strains mapped uniquely to 4,394,985 bases (99 %) of the KZN-4207 
reference genome (Table S3.1). The susceptible strain, KZN-V9124 had 43 nSNPs relative to KZN-
4207, of which 37 were unique and 6 were shared with the drug-resistant strains (Figure 3.2a)). 
Seven nSNPs were common to the MDR (KZN-V1435) and XDR strains (KZN-605 and KZN-
X162) of which 4 had no definitive link to drug resistance. Drug-resistant strains had previously 
reported mutations in resistance-conferring genes (Ioerger et al. 2009). Mapping of the XDR strains 
to KZN-4207 revealed 3 unique mutations in KZN-X162. Of these, one mutation (L129M) 
identified in the grcC1 gene (Rv0562) encoding polyprenyl-diphosphate synthase, was not detected 
in previously-sequenced KZN genomes. Fifteen frameshift mutations were identified in V1435 
(MDR) with respect to the Broad’s sequence (Table S3.4), as well as a nSNP in sigA, albeit with 
low read frequency (<70%). Sanger sequencing of sigA revealed the presence of two peaks at the 
target nucleotide site, confirming it was not a false positive. Fewer differences were evident 
between KZN605 and the previously-sequenced genome. These included 5 frameshift mutations (4 
in conserved hypothetical genes and 1 in a gene encoding a RifB protein) and 2 nSNPs in conserved 
hypothetical genes (Table S3.5). 
 
Mapping of Beijing strains to HN878 
A total of 120 and 135 nSNPs were detected in susceptible and MDR Beijing strains respectively, of 
which 65 were shared (Figure 3.2b). The majority of shared mutations (46 %) occurred within 
hypothetical proteins, underscoring the need for functional assignment to yet uncharacterised genes. 
Unique nSNPs in the susceptible strain included those in moaA1 and rpfB, whilst the MDR strain 
harboured nSNPs in sigK and double mutations in murD. 
 
Mapping of F11 strains to F11 reference 
A comparison of the susceptible and MDR F11 strains to the F11 reference genome revealed 54 and 
52 nSNPs, respectively (Figure. 3.2c). A total of 30 and 28 nSNPs were uniquely found in the 
susceptible and MDR strain, respectively. Of particular interest, was a Val104Leu mutation detected 
in the hrp1 gene (Rv2626c) of the susceptible strain. This gene is a member of the dormancy 
regulon and is strongly up-regulated under hypoxic conditions (Sharpe et al. 2008). The MDR strain 
harboured a mutation in vapC38 (Rv2494) which encodes a toxin previously shown to have 
increased expression during nutrient starvation, with plausible importance in the establishment of 





Figure 3.2 Venn diagrams depicting the distribution of non-synonymous single nucleotide 
polymorphisms in clinical strains. (a) F15/LAM4/KZN strains relative to KZN-4207, (b) Beijing 
strains relative to HN878, (c) F11 strains relative to F11 reference genome and (d) large indels (100 
– 500 bp) in F15/LAM4/KZN strains relative to H37Rv reference genome. DS: drug-susceptible, 
MDR: multidrug-resistant, XDR: extensively drug-resistant 
 
Drug resistance and efflux pumps 
Reads from the ten strains were uniquely mapped to an average of 4,341,256 bases (98.4 %) of the 
H37Rv reference genome (Table S3.3). A total of 50 mutations spanning 25 genes associated with 
drug resistance, were identified (Table 3.2). For INH resistance, we analysed katG, ndh, accD6, 
kasA, Rv1592c and mabA. Drug-resistant KZN and F28 strains had the canonical katG Ser315Thr 
mutation however different INH MICs (Table 3.3). Although the Beijing-MDR strain had a 
different substitution at codon 315, it maintained a comparably high INH MIC. In contrast, the F11 
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MDR strain possessed a rare katG mutation corresponding to the lowest INH MIC detected in this 
study. Mutations detected in ndh, accD6, kasA and Rv1592c did not correlate well with INH 
resistance as these were present in susceptible strains (Table 3.2). A recently characterised, 
mabAg609a silent mutation (Ando et al. 2014) was detected in our Beijing MDR strain. Drug-resistant 
KZN strains harboured a mutation (T1673432A) -8 upstream of mabA. 
 
Rifampicin-resistant strains exhibited mutations across five codons in rpoB. Interestingly, KZN-
V1435 had a secondary rpoB mutation which was reflected by 61% of the reads. Sanger sequencing 
indicated the presence of double nucleotide peaks (G and A) at position 1460, confirming it was a 
true variant (data not shown). Both susceptible and MDR Beijing strains harboured a sSNP in rpoB. 
The MDR-F28 strain possessed an rpoC compensatory mutation previously associated with the 
Ser450Leu rpoB mutation (de Vos et al. 2013), however only 42% of the reads reflected this SNP. 
Re-sequencing of rpoC revealed the presence of two peaks at nucleotide position 1448 (data not 
shown), confirming that it was a true variant.  
 
M. tuberculosis possesses three Emb homologs of which embA and embB which are co-transcribed; 
embC on the other hand is co-transcribed with dprE1, Rv3791 (dprE2) and Rv3792 (aftA) (Goude 
et al. 2008). Four embB mutations were observed in KZN, F11 and F28 resistant strains 
corresponding to different levels of EMB resistance (Table 3.3). The susceptibility of strains 
V9124, B910, R490 and R104 to EMB was confirmed by MICs equivalent to 1.875 mg/L. Despite 
having an embB mutation, the F11 MDR strain presented with a lower EMB MIC than the Beijing 
MDR strain without an embB mutation.  
 
For fluoroquinolone resistance, one of five gyrA mutations correlated with ofloxacin resistance 
(A90V), whilst others were common to both susceptible and resistant strains. All SNPs identified in 
our examination of gyrB, thyA, ddlA and gidB were present in both susceptible and -resistant strains, 








Table 3.2 Polymorphisms in genes associated with drug resistance  




Genotype  Strain (s) 
FQ Rv0005  gyrB  281CT P94L  F11  R490, R271 
Rv0006  gyrA  61GC E21Q All All 
269CT A90V F15/LAM4/KZN KZN605, X162 
284GC S95T All All 
739GA G247S F15/LAM4/KZN  V9124, V1435, KZN605, X162 
2003GA G668D All All 
ETH-
INH 
Rv0486 mshA 560CT A187V Beijing B910, R35 
Rv3199c nudC 716CG P239R Beijing B910, R35 
THZ Rv0644c mmaA2 639AC E213D Beijing B910, R35 
RIF Rv0667 rpoB 1303GT  D435T F15/LAM4/KZN V1435 
1304AG  D435G F15/LAM4/KZN KZN605, X162 
1349CT S450L F11, F28 R271, R443 
1355TC  L452P F15/LAM4/KZN; Beijing KZN605, X162; R35 
a1460AG N487S F15/LAM4/KZN V1435 
3225TC  -  Beijing B910, R35 
3317TC I1106T F15/LAM4/KZN KZN605, X162 
Rv0668 rpoC a1448TG  V483G F28 R443 
1626CG - F15/LAM4/KZN; F11 V9124, V1435, KZN605, X162; R490, R271 
INH Rv1483  mabA 609GA  - Beijing  R35 
Rv1592c  963AG  E321E Beijing B910, R35 
  964AG I322V Beijing B910, R35 
Rv1854c ndh 53TC V18A F28 R104  
Rv2245 kasA 805GA G269S F15/LAM4/KZN V9124, V1435, KZN605, X162 





604AG T202A F15/LAM4/KZN; F11 V9124, V1435, KZN605, X162; R490, R271 
Rv1908c katG 944GC S315T F15/LAM4/KZN; F28 V1435, KZN605, X162; R443 
944GT S315N Beijing R35 
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700GA G234R F11 R271 
1388GT R463L Beijing B910, R35 
CS Rv1704c cycA 278GT R93L All All 
Rv2981c ddlA 1093AG T365A F15/LAM4/KZN; F11; F28 V9124, V1435, KZN605, X162; R490, R271; R104, R443 
PZA Rv2043c  pncA  395GC G132A F15/LAM4/KZN V1435 
456_457insC T153fs F15/LAM4/KZN KZN605, X162 
EMB Rv3792 aftA 513GA - Beijing R35 
1032CT - F28 R104 
1343CG P448R F28 R104 
Rv3793 embC 2781CT - All All 
Rv3794 embA 228CT - Beijing B910, R35 
Rv3795  embB 916AG M306V F15/LAM4/KZN V1435, KZN605, X162 
918GC M306I  F28 R443  
1217GA  G406D F11 R271 
a1489CA G406K F28 R443 
Rv3806c ubiA 563TC V188A F15/LAM4/KZN KZN605, X162 
 112GT A38S F28 R443 
STR Rv3919c  gidB  47TG L16R F15/LAM4/KZN; F11 V9124, V1435, KZN605, X162; R490, R271 
583TC Y195H Beijing B910 
276AC  E92N Beijing B910, R35 
615AG - Beijing B910, R35 
KAN Rvnr01  rrs  1400AG  -  F15/LAM4/KZN KZN605, X162 
Rvnr02  rrl  2398GA  -  F15/LAM4/KZN KZN605, X162 
 
Drug resistance groups: FQ, fluoroquinolones; ETH-INH, ethionamide-isoniazid; THZ, thiacetazone; RIF, rifampicin; INH, isoniazid; CS, cycloserine; PZA, pyrazinamide; 







Table 3.3 Minimum inhibitory concentrations for isoniazid and ethambutol in clinical strains 
Strain Genotype Isoniazid MIC (µg/ml) Ethambutol MIC (µg/ml) 
V9124 F15/LAM4/KZN Susceptible 1.875 
V1435 F15/LAM4/KZN >16 ND 
KZN605 F15/LAM4/KZN >16 30 
X162 F15/LAM4/KZN >16 30 
B910 Beijing Susceptible 1.875 
R35 Beijing >16 7.5 
R490 F11/LAM3 Susceptible 1.875 
R271 F11/LAM3 1 5 
R104 F28/S Susceptible 1.875 
R443 F28/S 8 30 
Isoniazid (INH) and ethambutol (EMB) MICs were determined by the agar proportion method. Triplicate and duplicate 
experiments were performed for INH and EMB, respectively. The critical breakpoint for INH was 1 µg/ml and for EMB 
was 5 and 7.5 µg/ml. ND: not determined 
 
 
Previous studies have shown associations between drug efflux pumps and pathogenicity/virulence 
(Piddock 2006; Bina et al. 2009). Of the 36 SNPs occurring in 20 genes encoding drug efflux 
pumps, 31 (86 %) were present in susceptible strains (Table 3.4), suggesting that drug resistance is 
not always acquired by genetic modification of efflux pumps. Mutations in drrA and ctpB (G23S) - 
a gene believed to encode a putative copper transporter (Knapp et al. 2015), were uniquely present 












Table 3.4 Polymorphisms in known or putative drug efflux pumps in clinical strains  




Genotype Strain (s) 
Rv0050 ponA1 1891_1892 ins P631del ins PS F11, F28 R490, R271, R104, R443 
1891CT P631S F15/LAM4/KZN V9124, V1435, X162 
184_1885 ins P628_P629 ins P Beijing B910 
1891_1892 ins P631del ins PPS Beijing B910 
1891_1892 ins P631del ins PPPS Beijing R35 
Rv0103c ctpB 65TC L22S All All 
67GA G23S F15/LAM4/KZN V1435, KZN605, X162 
749CT A250V Beijing B910 
Rv0107c ctpI 4711_4712 ins T S1571fs All All 
3409GT V1137L Beijing B910 
Rv0174 mce1F 1109TC L370P All All except R104 
Rv0194  221TC Met74T All All  
3293CT P1098L Beijing B910, R35 
Rv0425c ctpH 2065AG M689V All  All  
197AC N66T F11 R490, R271 
Rv0507 mmpL2 1277GA R426H All All  
Rv0545c pitA 145CT P49S All All  
Rv0589 mce2A 152TC F51S All All  
Rv0676c mmpL5 2842AG I948V All All 
2381CT T794I Beijing B910, R35 
2299GA D767N Beijing B910, R35 
Rv1183 mmpL10 1222AG T408A Beijing B910, R35 
Rv1258c  580_581 insC E194fs Beijing B910, R35 
Rv1634  592GC G198R Beijing B910, R35 
Rv1730c  1483_1485 del  F495del Beijing B910, R35 
1305GC D435E Beijing B910, R35 
1326_1332 del  D442fs Beijing R35 
1313_1324 del T438_D442 del 
ins N 
Beijing R35 
Rv2687c  658CT R220W F15/LAM4/KZN V9124, V1435, KZN605, 
X162 
Rv2688c  466CA P156T All All 
Rv2936 drrA 784AG R262G F15/LAM4/KZN V1435, KZN605, X162 
Rv3331 sugI 116CT P39L F11 R490, R271 
1268CT P423L All All 
Rv3522 itp4 471GC W157C Beijing B910 
971CT T324I All All 
Rv3833  313GA V105I All  All  




Functional categorisation of SNPs 
Genes harbouring nSNPs relative to H37Rv were functionally categorised according to Tuberculist. 
The vast majority of nSNPs, regardless of strain family, were in genes encoding cell and cell wall 
processes followed by intermediary metabolism and respiration and conserved hypotheticals (Figure 
3.3). Closer examination of 13 genes encoding known virulence factors revealed clustering of strain 
genotypes with mutations in specific genes i.e. mmaA4 for KZN strains; glcB, fadD26, fadD28, 
plcA, plcC, mbtB and lipF for Beijing strains; narG and mmpL7 for F11 strains; and plcB for F28 
strains (Table 3.5). Whilst Beijing, F11 and F28 harboured distinct mutations in mas (Rv2940c), the 




Figure 3.3 Functional categorisation of genes with non-synonymous SNPs (nSNPs) in different 
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Table 3.5 Polymorphisms in genes encoding M. tuberculosis virulence factors 




Strain (s) Strain (s) 
Rv0642c mmaA4 494AG N165S F15/LAM4/KZN V9124, V1435, 
KZN605, X162 
Rv1161 narG 2999GA R1000H F11 R490, R271 
Rv1837c glcB 310GA G104S Beijing B910, R35 
Rv1860 apa 406TC F136L All All 
Rv2349c plcC 1081GT G361C Beijing B910, R35 
Rv2350c plcB 1406TC L469S F28 R104 
Rv2351c plcA 1336AG T466A Beijing B910, R35 
Rv2383c mbtB 2020GC V647L Beijing B910, R35 
Rv2930 fadD26 338CA S113Y Beijing B910 





3044AC D1015A F11 R490 
6013AC T2005P Beijing B910, R35 
Rv2941 fadD28 1306AG T436A Beijing B910, R35 
Rv2942 mmpL7 1651GA A551T F11 R490 
Rv3487c lipF 697CT R233C Beijing B910, R35 
 
Indels 
Indels represent a significant source of phenotypic variability and may enhance the pathogenesis of 
infectious agents (Liu et al. 2014). Small (<100 bp) and large (100 – 500 bp) insertions and 
deletions were analysed in strains relative to H37Rv. In total, 562 small indels and 207 large indels 
were identified in all strains, of which 96 were in PE-PPE-PGRS regions - a significant source of 
antigenic variability (Sampson 2011). Within the KZN group, 2 indels i.e. a large deletion (321 bp) 
and insertion (124 bp), were shared amongst all 4 strains in Rv0145 and Rv2112c, respectively (Fig. 
3.2d). Susceptible strains, KZN-V9124 and F28-R104 harboured the highest (57) and lowest 
number (8) of large indels, respectively. A higher degree of overlap was observed within the Beijing 
group, with 15 shared indels spanning PPE-PE-PGRS regions, hypothetical genes and 
transmembrane proteins.  
 
DISCUSSION 
In our previous study, we showed that specific genotypes i.e. F15/LAM4/KZN and F28 were better 
suited to drug-resistant forms than Beijing and F11 strains, in terms of their in vitro fitness (Naidoo 
and Pillay, 2014). In the current study, we addressed the role of resistance-conferring mutations 
and/or compensatory mutations in the fitness of these clinical strains. Mapping of the KZN 
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susceptible strain (V9124) to the reference genome (KZN-4207) revealed a surprising number (43) 
of nucleotide variations. This genetic dissimilarity between both susceptible strains most likely 
accounts for our previous observations, whereby resistant strains exhibited differential growth when 
paired with V9124 or KZN-V4207 in competitive growth assays (Naidoo and Pillay, 2014).  
 
The KZN-MDR strain, V1435, contained a novel, low-frequency sigA mutation that was absent in 
the KZN 1435 genome previously sequenced by the Broad Institute. Moreover, this mutation was 
undetected in other strains sequenced in this study. Since variants with at least 30% of the Illumina 
reads reflecting a SNP can exist as sub-populations within the M. tuberculosis genome (Black et al. 
2015), we re-sequenced the sigA gene. Double peaks were observed in the Sanger chromatogram, 
confirming it as a true variant. An earlier study showed attenuation of an M. bovis strain carrying a 
sigA mutation (Collins, 1995) while a later study showed that the overexpression of the sigA gene 
enhanced intracellular growth in macrophages and mouse lungs (Wu et al. 2004). V1435 
demonstrated comparable growth to V9124, KZN605 and X162 in laboratory culture (Naidoo and 
Pillay, 2014) however the virulence of this strain remains to be determined. Mapping of the XDR 
strain, KZN605 to the previous version revealed fewer genetic differences that were predominantly 
observed in hypothetical genes, thus their significance remains elusive. Overall, we speculated that 
these changes were due to adaptation during laboratory culture (although passages were kept to a 
minimum) or could reflect differences in read depth.  
 
Comparative assessment of the KZN XDR strains revealed the presence of some formerly reported, 
as well as a unique mutation in the grcC1 gene of X162 - a mutation that was unreported in any of 
the previously-sequenced KZN-XDR strains (Ioerger et al. 2009). Intriguingly, this mutation was 
one of 3 grcC1 mutations detected in an outbreak strain which infected 69 patients in Bern, 
Switzerland (Stucki et al. 2015). Orthologs of this essential gene (in M. tuberculosis) are highly 
conserved across the mycobacteria family, advocating the potential significance of this gene in 
isoprenoid metabolism (Mann et al. 2012). Mutations that were shared, yet uniquely present in the 
KZN XDR strains, were found in Rv2000 (L275P) and Rv3471c (D64E), as previously reported 
(Ioerger et al. 2009). Overexpression of Rv2000 in a recent study resulted in no change in 
susceptibility to EMB, kanamycin, rifampicin and streptomycin (He et al.2015). Thus, their role in 
drug resistance or epistatic interactions remains to be determined. In addition to the canonical 
M306V embB mutation, both XDR strains harboured an accessory mutation in Rv3806c (ubiA), 
which functions to increase EMB resistance without imposing fitness deficits (Safi et al. 2013).  
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Because mutations in the rifampicin-resistance determining region (RRDR) are associated with 
fitness costs, the presence of intragenic mutations in highly transmissible strains is worthy of closer 
inspection. Drug-resistant KZN strains in this study harboured previously-reported secondary 
(N568S) and tertiary (I1187T) mutations outside the RRDR (Ioerger et al. 2009) which represent 
putative compensatory mutations (Cohen et al. 2015). Further research with isogenic mutants may 
provide more insight regarding the level of compensation offered by such mutations in the evolution 
of fit drug-resistant strains.  
 
HN878 was selected as a reference for Beijing strains on the basis of its pan-susceptibility and 
widespread inclusion in comparative studies (Manca et al. 2001). Both Beijing strains had gyrA 
Ser95Thr and katG R463L mutations, verifying that they belonged to principle genetic group 1 
(Sreevatsan et al. 1997). The rpoB sSNP present in both Beijing strains was shown to be a 
phylogenetic marker rather than a predictor of rifampicin resistance (Comas et al. 2012). 
Synonymous SNPs (sSNPs) are believed to have little effect on bacterial phenotype or fitness, 
however some sSNPs have been shown to play an important role in the generation of alternative 
transcriptional start sites (Coscolla and Gagneux 2014). In addition to the katG alteration, the 
Beijing MDR strain had a synonymous G609A mutation in the mabA gene. Commonly found in 
INH-resistant clinical isolates, this synonymous mutation results in the amplification of 
transcriptional levels of inhA, and may represent an alternative mechanism of INH resistance in M. 
tuberculosis (Ando et al. 2014). Similarly, synonymous mutations in Rv3792 are believed to 
increase EMB MICs by upregulating embC, explaining the increased EMB MIC of the Beijing 
MDR strain relative to susceptible strains. Given that Ser315Asn katG mutants exhibit nearly half 
the catalase-peroxidase activity of Ser315Thr mutants (Unissa et al. 2012) and that no 
compensatory mutations related to INH and rifampicin resistance were identified, the reduced in 
vitro fitness of the Beijing MDR strain is hardly surprising. While the Beijing genotype is highly 
transmissible in its susceptible form, it does not disseminate equally well in drug-resistant forms 
(notably XDR) in South Africa, and is most likely due to high fitness costs associated with drug 
resistance (van de Spuy et al. 2009; Ioerger et al. 2010). This is supported by the diversity of 
resistance-encoding mutations among XDR Beijing strains from South Africa (Ioerger et al. 2010), 
Russia (Casali et al. 2014) and Japan (Iwamoto et al. 2008), suggesting that mutations are 




Clinical strains which harbour identical resistance-conferring mutations may demonstrate variable 
MICs (Kim et al. 2003). This was the case for KZN and F28 drug-resistant strains which had 
different INH MICs despite sharing the same katG S315T mutation. Whilst the S315T mutation 
confers little or no fitness cost, other katG mutants may be compensated by ahpC mutations which 
ameliorate catalase-peroxidase activity (Sherman et al. 1996). Likewise, the fitness of rifampicin-
resistant strains harbouring rpoB mutations may be restored by rpoC compensatory mutations (de 
Vos et al. 2013). Even though both F11 and F28 MDR strains possessed a S531L mutation, only the 
F28 strain had an rpoC mutation, explaining its high fitness (Naidoo and Pillay, 2014). The finding 
that only 42 % of the reads reflected the rpoC SNP indicates that the genome was in the process of 
acquiring compensation in response to a changing environment (Black et al. 2014). Furthermore, 
36% of the mapped reads from the F28 MDR strain reflected a newly-identified nSNP (A38S) in 
ubiA. The significance of this SNP in EMB resistance and compensation requires further study. We 
surmise that the absence of compensatory ahpC and rpoC mutations to complement the rare katG 
and S351L rpoB mutations in the F11 MDR strain may explain its marked reduction in fitness, as 
evidenced by previous growth and metabolic assays (Naidoo and Pillay 2014). Although the F11 
MDR strain had a G406D embB mutation, this strain was susceptible to EMB at the critical 
breakpoint of 5 mg/L, substantiating that this mutation confers a low level of resistance.  
 
We acknowledge that the whole genome sequencing of a greater number of strains would provide 
an improved framework for the detection of strain-specific SNPs associated with drug resistance 
and physiological fitness. However, due to financial constraints, we limited the number of strains 
sequenced to those used in our previous biological fitness and competitive assays. A selection of 
low-frequency alleles was verified by Sanger sequencing, all of which proved to be true variants. 
This supports a recent study by Black et al. (2015) which demonstrated that significant SNPs may 
be missed at higher frequency cut-offs. The presence of subpopulations within the M. tuberculosis 
genome raises the question of how genetic heterogeneity shapes treatment outcomes, especially in 
highly endemic regions e.g. South Africa, where selection of drug resistance is significantly 
influenced by TB control programmes (Chihota et al. 2012; Muller et al. 2013).  
 
Whole-genome sequencing provides an ideal platform for comparative analysis of dominant strains 
to better understand drug resistance and fitness-compensatory mutations. Whilst there are certain 
limitations to experimental models, we and others (Gagneux et al. 2006; Spies et al. 2012) have 
shown that laboratory studies are crucial in understanding the effects of resistance-encoding 
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mutations on replicative fitness. Further studies evaluating the fitness of highly circulating strains 
may provide added insight on their epidemiological success and possibly reveal new ways to 
combat TB. Clinical strains possess considerable genetic diversity which may influence 
physiological fitness i.e. growth characteristics, virulence and transmissibility. The results of this 
study corroborate our previous work which showed that 1) specific genetic backgrounds are better 
suited to coping with drug resistance i.e. F15/LAM4/KZN and F28 strains and 2) resistance-
conferring mutations with the lowest fitness costs are favoured in highly transmissible strains. 
Whole-genome sequencing also revealed the presence of novel SNPs in drug-resistant 
F15/LAM4/KZN strains, some of which may serve as fitness-compensatory mutations.  
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The F15/LAM4/KZN (KZN) genotype is frequently associated with multidrug resistance (MDR) 
and extensive drug-resistance (XDR) in KwaZulu-Natal, South Africa. Ten clinical strains, 
representing KZN and other predominant genotypes, and H37Rv were used to infect THP-1 
macrophages. Uptake and intracellular growth indices were measured at 4 hours and on day 5, 
respectively. In addition, 17 cytokines were examined at both intervals in M. tuberculosis-infected 
macrophage supernatants, using a commercial multiplex cytokine assay. There were no significant 
differences for uptake by macrophages. The MDR KZN strain presented with the highest growth 
index (1.64 ± 0.05), followed closely by one of two XDR KZN strains (1.59 ± 0.02), while the other 
(X162) had comparable replication to the susceptible KZN strain. High levels of IL-1β and MIP-1β 
elicited by X162 early in infection may have limited its replication. H37Rv had the lowest growth 
index (1.36 ± 0.03). XDR KZN strains elicited higher levels of TNF-α compared with other strains 
(p<0.05) and uninfected macrophages at 4 hours. These strains may exploit the secretion of TNF-α 
for tissue destruction and ultimately, its transmission to other hosts. Increasing levels of MIP-1β 
production corresponded with increasing degrees of drug resistance in KZN strains, while no clear 
trends were observed between remaining cytokines and drug resistance in this genotype. Although 
exhibiting similar replication, susceptible and MDR strains within Beijing, F11 and F28 genotypes 
produced heterogeneous cytokine responses. The lack of a direct relationship between bacillary 
burden and cytokine responses indicate that this diversity results from strain heterogeneity.  
 
INTRODUCTION 
Tuberculosis (TB) and the human immunodeficiency virus (HIV) are the primary contributors to 
mortality resulting from infectious diseases, with strategies to combat these diseases often hampered 
by drug resistance (WHO, 2014). Upon inhalation, M. tuberculosis bacilli are delivered to the 
alveolar spaces of the lung where they encounter macrophages. During infection with M. 
tuberculosis, these professional phagocytes engulf and process infectious bacilli, and present them 
to other immune cells (Hocking et al., 1979). Some bacilli however, are able to survive and 
replicate regardless of the harmful nitric oxide (NO) and reactive nitrogen intermediates (RNI) 
present within phagosomes and may even prevent phagosome-lysosome fusion (reviewed in Ehrt 
and Schnappinger, 2009). The ability of mycobacteria to resist RNI is believed to be dependent on 
the strain, dose and time (O' Brien et al. 1994; Rhoades and Orme, 1997; Long et al. 1999; Long et 
al. 2005). Alveolar macrophages play an integral role in connecting innate and adaptive immunity 
within hosts (Flynn and Chan, 2003). One of the key determinants in the progression of TB 
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infection is the production of cytokines/chemokines, which orchestrate the containment of 
infectious organisms and granuloma formation (Fuller et al. 2003; Mihret and Abebe, 2013). Both 
interferon gamma (IFN-γ) and tumour necrosis factor alpha (TNF-α) have been described as the 
forefront cytokines in the antimycobacterial Th1 pathway (Lin and Flynn, 2010).   
 
Since macrophages are critical for intracellular replication and survival of M. tuberculosis, 
extensive research has focused on establishing immunological, genetic and physiological properties 
of M. tuberculosis-macrophage interactions (Schnappinger et al., 2003; Rengarajan et al., 2005; 
Giacomini et al., 2001). Studies employing cell culture and mouse models have demonstrated that 
strains of different M. tuberculosis genotypes display variability in immune responses (Hoal-van 
Helden et al. 2001; Lopez et al. 2003; Chacón-Salinas et al. 2005; Sarkar et al. 2012; Chakraborty et 
al. 2013). Moreover, virulent strains tend to exhibit increased growth and survival in macrophages 
(Silver et al. 1998; Zhang et al. 1998; Park et al. 2006; Rajavelu and Das, 2007). Data for Beijing 
strains are conflicting, with some studies reporting low proinflammatory responses and growth rates 
compared to other genotype strains in macrophages (Tanveer et al. 2009; Chakraborty et al. 2013), 
and others reporting high production of TNF-α in human macrophages (Chacón-Salinas et al. 2005). 
Beijing strains have also to be shown to cause higher mortality rates in BALB/c mice compared to 
H37Rv (Lopez et al. 2003). Survival times of SCID mice infected with F15/LAM4/KZN strains 
varied, with susceptible strains causing rapid mortality compared with strains carrying multidrug-
resistance (MDR) and extensive drug-resistance (XDR) (Smith et al. 2014). 
 
Drug-resistant strains sometimes undergo fitness costs, depending on the resistance-encoding 
mutations they harbour and their genetic background (Gagneux et al. 2006). Fitness costs refer to 
decreased growth rates, virulence or transmission efficiencies that are measureable in specific 
environments (Andersson and Hughes, 2008). The in vitro growth rates of four clinically-relevant 
genotypes that predominate in KwaZulu-Natal, South Africa were previously characterised (Naidoo 
and Pillay, 2014) however their virulence properties remained to be determined. Increased fitness 
was observed for drug-resistant F15/LAM4/KZN and F28 genotype strains, contrasting with Beijing 
and F11 MDR strains which had incurred fitness costs (Naidoo and Pillay, 2014). In the current 
study, as surrogates of fitness, we assessed uptake, intracellular growth and cytokine responses of 
the same clinical strains with different genotypes and levels of drug resistance, in THP-1 
macrophages. The 17-plex kit was selected on the basis of its inclusion of several proinflammatory 
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M. tuberculosis strains 
The H37Rv laboratory reference strain and ten clinical strains comprising drug-susceptible, MDR 
and XDR types were included in this study (Table 4.1). Strains were cultured in Middlebrook 7H9 
broth (Difco) supplemented with 10 % oleic acid albumin dextrose (OADC) enrichment (Becton 
Dickinson), 0.5 % glycerol and 0.05 % Tween-80 until an optical density (OD600) of 0.6-1.  
 
 
Table 4.1 M. tuberculosis strain profiles 
Strain Genotype Type a Drug resistance b 
V9124 F15/LAM4/KZN DS - 
V1435 F15/LAM4/KZN MDR IR 
KZN605 F15/LAM4/KZN XDR IRSEOKCN 
X162 F15/LAM4/KZN XDR IRSEOKCN 
B910 Beijing DS - 
R35 Beijing MDR IRS 
R490 F11/LAM3 DS - 
R271 F11/LAM3 MDR IR 
R104 F28/S DS - 
R443 F28/S MDR IRSEK 
H37Rv Laboratory reference DS - 
a DS: drug-susceptible; MDR: multidrug-resistant, XDR: extensively drug-resistant 









The THP-1 human derived macrophage cell line (ATCC TIB-202) was propagated in RPMI-1640 
(Lonza) containing 10% foetal bovine serum (Biowest) (RPMI-C) at 37 °C (with 5% CO2). Cells 
were enumerated by trypan blue exclusion prior to reconstitution with phorbol 12-myristate 13-
acetate (50 ng/ml) for overnight differentiation into macrophages. Cells were seeded at 2 X 105 
cells/ml in 24-well cell culture plates (Porvair) for intracellular growth assays, or in 25 cm2 flasks 
(Porvair) for cytokine analysis.  
 
Macrophage infection  
Bacterial cultures were pelleted by centrifugation at 2000 x g for 10 minutes and resuspended in 1 
mL of RPMI-C. Bacteria were passaged 10 times through a 21-gauge needle (attached to a 1-ml 
syringe) and diluted to 2 X 105 bacteria per ml in RPMI-C. Following overnight incubation, 
monolayers were washed twice with warm PBS to remove non-adherent cells. Infection media was 
freshly prepared immediately before use. Macrophages were infected, in triplicate wells, at a 
multiplicity of infection (MOI) of 1:1. After 4 hours of incubation at 37 °C (5 % CO2), monolayers 
were washed three times with warm PBS to remove extracellular bacteria and fresh media was 
added to day 5 wells. For colony forming unit (CFU) enumeration at 4 hours and 5 days post-
infection, macrophages were lysed for 20 minutes with 0.1 % Triton X-100. Serially-diluted lysates 
were plated, in triplicate, onto Middlebrook 7H10 medium (Difco) containing 10 % OADC and 
0.5% glycerol and incubated for 3 weeks at 37 °C. Three independent macrophage experiments 
were performed for each strain. To confirm the MOI during each experiment, bacterial inocula was 
plated onto Middlebrook 7H10 medium and incubated for 3 weeks. 
 
Cytokine determination 
For cytokine analysis, macrophages were infected as described above in 25 cm2 flasks (10 ml) at an 
MOI of 1:1. Cell-free culture supernatants were collected after 4 hours and 5 days of infection by 
filtering through 0.22 µm units. Supernatants were reconstituted with 0.5% bovine serum albumin 
(BSA) prior to storage at -70 °C. The Bio-Plex Pro ™ Human Cytokine 17-plex assay (Bio-Rad) 
was performed according to the manufacturer's instructions. Briefly, a standard curve was generated 
by serially-diluting cytokine standards in RPMI-C (with 0.5% BSA) to ensure comparability to 
samples. Each strain was tested in triplicate wells from one representative experiment. A 50 µl 
volume of samples, uninfected  controls (day 0 or day 5), blank (medium only) and cytokine 
standards was added to a 96-well plate containing 50 µl of coupled beads, and incubated with gentle 
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shaking (at room temperature) for 60 minutes. Detection antibodies and streptavidin-PE were added 
to the plate with incubation and washing steps preceding each addition. After the last wash step, 125 
µl of assay buffer was added to each well and the plate was read on the Bio-Plex array reader. 
Cytokine data analysis was performed using the Bio-Plex Manager software, version 6.1.   
 
Statistical analysis 
Intracellular uptake and growth indices were analysed by one-way ANOVA with Fisher’s LSD test, 
using SPSS v.22.0 (IBM Statistics). Cytokine responses were analysed by one-way ANOVA with 
Tukey’s post-hoc test. A p value less than 0.05 was statistically significant. 
 
Ethical approval 
This study was approved by the Biomedical Review Ethics Committee at the University of 




Uptake by macrophages 
Four KZN (one susceptible, one MDR and two XDRs) and two strains (one susceptible and one 
MDR) of Beijing, F11 and F28 genotypes were used to infect THP-1 macrophages. Mycobacterial 
uptake was measured by dividing the number of CFU/ml at 4 hours by the number of CFU/ml in the 
starting inoculum (Figure 4.1A). No statistically significant differences were observed at 4 hours 
however, some general observations were made. Beijing and F11 strains had similar uptake at 4 
hours post-infection, with the MDR strains being taken up two to three times more efficiently by 
macrophages, than susceptible strains and H37Rv. The reverse was observed for KZN and F28 
genotypes, with higher uptake levels for susceptible strains. 
 
Intracellular growth 
Intracellular growth was calculated as the CFU/ml on day 5 divided by the CFU/ml at 4 hours. The 
KZN MDR strain, V1435 had the highest growth index of 1.64 ± 0.05, followed closely by the 
XDR strain, KZN605 (1.59 ± 0.02) (Figure 4.1B). Despite high initial uptake, the susceptible KZN 
strain, V9124 had a lower growth index than V1435 (p=0.009) and the XDR strain, KZN605 
(p=0.031), but equivalent growth to the other XDR strain, X162. Susceptible strains within Beijing, 
F11 and F28 genotypes had similar growth indices to MDR strains. H37Rv had the lowest growth 
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index (1.36 ± 0.03); this was significantly lower than V1435 (p=0.004), KZN605 (p=0.016) and 


















Figure 4.1 Uptake and intracellular growth indices of M. tuberculosis strains in THP-1 
macrophages. (A) Strain uptake was calculated as the CFU/ml at 4 hours divided by the CFU/ml in 
the starting inoculum, expressed at a percentage (mean ± SE). (B) Intracellular growth indices were 
calculated as the log CFU/ml on day 5 divided by the log CFU/ml at 4 hours (mean ± SD). Data 
represents three independent experiments. Purple bars: F15/LAM4/KZN strains, red bars: Beijing 
strains, yellow bars: F11 strains, blue bars: F28 strains. S: drug-susceptible, M: multidrug-resistant, 










Cytokine responses at 4 hours 
Of 17 cytokines examined, interleukin (IL)-5, IL-7 and IL-13 were undetected. Uninfected THP-1 
macrophages produced relatively high levels of cytokine production. This is in accordance with a 
study by Aldo et al. (2013) which demonstrated that uninfected macrophages produce high levels of 
proinflammatory cytokines in response to PMA-differentiation. The following cytokines were 
elicited at 4 hours: TNF-α, IL-1β, IL-2, IL-8, IL-17, granulocyte-colony stimulating factor (G-CSF), 
monocyte chemotactic protein-1 (MCP-1) and macrophage inflammatory protein -1β (MIP-1β) 
(Figure 4.2). Overall, the most highly expressed cytokines were IL-1β, IL-8, MCP-1 and MIP-1β. 
With the exception of the KZN605 and R35, similar cytokines responses were detected amongst all 
strains for IL-2, IL-8 and G-CSF at 4 hours.  
 
Within the KZN genotype, increasing levels of MIP-1β were observed for KZN strains, with X162 
exhibiting the most, followed by KZN605 and V1435 with intermediate levels, and V9124 with the 
least. This was significant between the XDR strains and the susceptible strain (p<0.001), X162 vs. 
the MDR strain (p<0.001) and KZN605 (p=0.012). X162 also had higher expression of IL-1β 
compared to V9124 and KZN605 at 4 hours (p<0.001). The XDR strains, KZN605 and X162, were 
the strongest inducers of TNF-α at 4 hours (vs. R490: p=0.007 and p=0.012, respectively, vs. 
H37Rv: p=0.004 and p=0.007, respectively and vs. all other strains: p<0.001). KZN strains had 
similar responses for remaining cytokines at 4 hours.  
 
The Beijing susceptible strain (B910) had higher secretion of IL-1β (p=0.006) than the MDR strain 
(R35), while similar responses were observed for other cytokines. Compared to its MDR 
counterpart (R271), the susceptible F11 strain (R490) had higher production of IL-1β (p<0.001), 
MIP-1 (p=0.013) and TNF-α (p=0.006) at 4 hours. F28 strains did not differ in their cytokine 
responses at 4 hours. Interestingly, H37Rv and R104 had comparable cytokine responses with the 



































































































































































































































































































































































































































































































































































































Figure 4.2 Cytokines detected in the supernatants of M. tuberculosis-infected THP-1 macrophages 
at 4 hours. Purple bars: F15/LAM4/KZN strains, red bars: Beijing strains, yellow bars: F11 strains, 
blue bars: F28 strains. Data represents the mean ± SD. S: drug-susceptible, M: multidrug-resistant, 
X: extensively drug-resistant 
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Cytokine responses at 5 days 
Cytokines IL-4, IL-6, IL-10, IL-12 (p70), IFN-γ and granulocyte macrophage-colony stimulating 
factor (GM-CSF) were secreted on day 5 only (Figure 4.3) while others i.e. TNF-α, IL-1β, IL-2, IL-
8, IL-17, G-CSF and MCP-1 (Figure 4.4) were secreted at both time points. Similar cytokines 
responses were detected for IL-10, IL-12 (p70) and IL-17, with the exception of KZN605 and R35, 
which produced significantly higher amounts of cytokines than other strains, particularly MCP-1 at 
5 days (p<0.001).  
 
For IL-1β, V9124 and KZN605 had higher production than X162 and V1435 (p<0.001). The 
Beijing MDR strain, R35 had significantly higher secretion of ten cytokines including IL-1β, IL-2, 
IL-4, IL-6, IL-10, G-CSF, GM-CSF, MCP-1, TNF-α and IFN-γ than the susceptible Beijing strain 
on day 5 (p<0.05). More significant differences were observed between the F28 strains on day 5, 
with the susceptible strain (R104) eliciting significantly higher levels of IL-1β (p<0.001), IL-6 
(p=0.001) and GM-CSF (p=0.039) than the MDR strain (R443). In contrast, R443 did not induce 
significantly higher levels of any cytokines compared to R104. Notably, H37Rv had the highest 











































































































































































































































































































































































































Figure 4.3 Cytokines detected in the supernatants of M. tuberculosis-infected THP-1 macrophages 
on day 5 only. Purple bars: F15/LAM4/KZN strains, red bars: Beijing strains, yellow bars: F11 
strains, blue bars: F28 strains. Data represents the mean ± SD. S: drug-susceptible, M: multidrug-


















































































































































































































































































































































































































































































































































































Figure 4.4 Cytokines detected in the supernatants of M. tuberculosis-infected THP-1 macrophages 
on day 5. Purple bars: F15/LAM4/KZN strains, red bars: Beijing strains, yellow bars: F11 strains, 
blue bars: F28 strains. Data represents the mean ± SD. S: drug-susceptible, M: multidrug-resistant, 




Strain-specific variation has been increasingly demonstrated to play a significant role in virulence 
and immunogenicity in recent years. Using diverse clinical strains from South Africa, we addressed 
the effect of genotype and drug resistance on mycobacterial fitness, in the form of intracellular 
replication and cytokine induction at two different time points in macrophages. Similar to recent 
studies (Sarkar et al. 2012; Chakraborty et al, 2013), we found no significant differences in the 
uptake efficiencies of clinical strains however our findings differed for Beijing (and two KZN) 
strains which had significantly higher intracellular growth than H37Rv. 
 
The majority of cytokines were low or undetected at 4 hours, however interesting patterns of 
expression were observed for IL-1β, MIP-1β and TNF-α. While increasing levels of MIP-1β and 
TNF-α corresponded with increasing degrees of drug resistance in KZN strains (i.e. XDR > MDR > 
susceptible), the reverse was observed for F11 strains, whereby the susceptible strain induced 
significantly higher production. Likewise, susceptible Beijing and F11 strains which exhibited 
higher IL-1β production than MDR strains contrasted with the KZN genotype, which did not show 
any correlation between IL-1β production and drug resistance.  
 
Recent work demonstrated increased necrosis/cytotoxicity in A549 epithelial cells following 
infection with XDR KZN strains however the role of TNF-α was not explored (Smith et al. 2014; 
Ashiru and Sturm, 2015). TNF-α has been described as a ‘double-edged sword’: it not only controls 
M. tuberculosis infection but also causes extensive tissue destruction (reviewed in Mootoo et al. 
2009). In this study, XDR strains were the highest inducers of TNF-α at 4 hours post-infection. 
Increased production of TNF-α has been reported previously by highly virulent isolates in human 
monocytes and macrophages (Valway et al. 1998; Engele et al. 2002. We speculate that the XDR 
KZN strains may exploit the secretion of TNF-α for cell necrosis, thereby increasing their chances 
of being released into surrounding tissues (Bocchino et al. 2005; Vandenabeele et al. 2010).  
 
While cytokines may be secreted by either T helper cells 1 (Th1) or 2 (Th2), the cell-mediated 
immune response to TB is primarily driven by Th1 secretion of cytokines, including IFN-γ. This 
cytokine is responsible for the induction of antimicrobial activity by macrophages (Condos et al. 
2003; Wallis 2005; Park et al. 2007), whereby IFN-γ inhibits IL-4 production but promotes the 
secretion of IL-12 (p70) and together, these cytokines direct microbial recognition by innate 
effector cells (Rivero-Lezcano, 2008). Previous studies show that TB patients with predominantly 
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Th1 cytokines (i.e. IFN-γ), experience milder forms of pulmonary disease, whereas patients with 
high levels of Th2 cytokines (i.e. IL-4) have more severe forms of disease (Dlugovitzky et al. 1997; 
Dlugovitzky et al. 1999). Moreover, MCP-1 is able to activate the promoter of IL-4, thereby 
enhancing the Th2 response (Karpus et al. 1997). 
 
In our current study, IFN-γ, IL-4 and IL-12 (p70) were only detected on day 5, with IFN-γ having 
the highest response and IL-4 having the lowest response. No significant differences were observed 
in the induction of IL-12 (p70), however nine of 11 strains produced three to six-fold more IL-12 
(p70) than IL-4. The remaining strains, KZN605 and R35, had similar IL-4 levels (3.36 and 2.77 
pg/ml, respectively) to IL-12 (p70) (4.16 and 4.12 pg/ml, respectively). Moreover, while other 
strains appeared to suppress IL-4 and MCP-1 production on day 5, KZN605 and R35 produced 
significantly higher amounts than these strains (p<0.01 except IL-4: R35 vs. R104 where p=0.047). 
Increasing levels of these cytokines may lead to higher morbidity/mortality in individuals infected 
with these mycobacterial strains, as elevated IL-4 expression is often associated with tissue 
destruction and apoptosis (Seah et al. 2001). This is also supported by the fact that KZN605 is a 
member of the historical XDR- F15/LAM4/KZN clone associated with rapid disease progression 
and time to death of 52 of 53 HIV-infected patients in Tugela Ferry in 2005 (Gandhi et al. 2006).  
 
Beijing isolates are believed to induce low levels of pro-inflammatory cytokines such as IL-6, IL-10 
and TNF-α relative to H37Rv and clinical isolates in vitro (Reed et al. 2004; Wang et al. 2010). In 
the present study, this was observed for the susceptible strain only, whereas the MDR strain, R35 
had induced significantly higher production of these and most other cytokines (including IFN-γ, 
p=0.013) compared to H37Rv and clinical strains. Interestingly, R35 possesses a non-synonymous 
mutation in a gene encoding a mammalian cell entry family protein, mce1C (Rv0171) (Naidoo and 
Pillay, 2015, submitted) which could be associated with its virulence in THP-1 macrophages, 
however, this needs clarification by further research.  
 
Despite commencing experiments with similar MOIs, strains within, and among, genotypes 
displayed differential replication and cytokine responses i.e. Beijing strains exhibited similar 
replication but differed in cytokine induction, with the MDR strain being highly immunogenic. F11 
strains replicated at similar rates but differed in some of their cytokines responses, with the 
susceptible strain eliciting significantly higher levels of IL-1β, MIP-1 and TNF-α following 
phagocytosis at 4 hours. Similarly, F28 strains which had comparable replication, differed in their 
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secretion of cytokines with the susceptible strain producing significantly more IL-1β, IL-6 and GM-
CSF than the MDR strain on day 5. Thus, there appears to be no direct relationship between 
intracellular bacillary burden and cytokine responses in macrophages, but is rather a reflection of 
strain heterogeneity. 
 
The increased intracellular replication of two drug-resistant KZN strains (including the outbreak 
strain KZN605) confirms that little or no fitness costs accompany their infection of THP-1 
macrophages. Inconsistent findings in the other XDR strain may be explained by the high levels of 
IL-1β and MIP-1β produced during the first 4 hours of infection which could have limited its ability 
to replicate thereafter, although not to a level below that of the susceptible KZN strain. Indeed, 
MIP-1β being one of the main beta-chemokines produced during M. tuberculosis infection has been 
shown to suppress mycobacterial growth (Saukkonen et al. 2002). MDR strains from Beijing and 
F11 genotypes which had comparable growth indices to susceptible strains in macrophages, 
demonstrated significant fitness costs in laboratory medium (Naidoo and Pillay, 2014), affirming 
that in vitro fitness does not always correlate with in vivo fitness. Only two time points were 
measured in this study, thus the long-term growth kinetics of these strains in other models of 
infection remains to be determined.  
 
Extensive tissue destruction due to increased TNF-α production may have contributed to the high 
mortality rates caused during the Tugela Ferry XDR-TB outbreak (Gandhi et al. 2006). While KZN 
strains displayed diverse phenotypes associated with drug resistance, no clear associations could be 
made for MDR Beijing, F11 and F28 genotype strains and their cytokine responses. Thus, this study 
provides further evidence that clinical strains exhibit heterogeneous virulence properties, and 
necessitates additional research to determine how these differences influence TB infection, disease 
progression and outcome in human hosts. 
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Tuberculosis retreatment cases are often associated with low cure rates and increased risk for the 
development of drug-resistant TB. In this study, three HIV-positive patients who had successfully 
completed anti-tuberculosis treatment later developed relapse, despite improved overall health 
status. The in vitro fitness of paired M. tuberculosis isolates was investigated as a putative 
contributor to relapse. DNA fingerprint patterns of paired isolates were verified by IS6110-
restriction fragment length polymorphism typing and spoligotyping. Drug susceptibility profiles, in 
vitro growth and drug resistance-encoding mutations were compared between initial and relapse 
isolates. Each patient harboured isolates with identical fingerprint patterns, drug susceptibility 
profiles, minimum inhibitory concentrations and mutations at initial infection and relapse. Growth 
rates were indistinguishable for initial and relapse isolates on day 12, as measured by colony counts. 
Although some differences were evident on day 20, these did not achieve statistical significance. 
Taken together, these findings supports the assertion that isolates recovered at the time of relapse 
most likely represents primary-infecting isolates. Importantly, this preliminary study shows that M. 
tuberculosis isolates may reactivate without significant changes in in vitro fitness, despite prolonged 
exposure to anti-tuberculosis drugs and host immunity. 
 
INTRODUCTION 
The World Health Organization estimated that 13 % of the 9 million individuals with tuberculosis 
(TB) in 2013 were co-infected with the human immunodeficiency virus (HIV) (WHO, 2014). HIV 
facilitates the progression to active TB disease (Daley et al. 1996) causing high rates of mortality 
(Sileshi et al. 2013), and is also a notable risk factor for TB recurrence (Sonnenberg et al. 2001). 
Mycobacterium tuberculosis isolates causing recurrence can be classified into two groups: the 
diagnosis of TB with an isolate having a restriction fragment length polymorphism (RFLP) pattern 
similar or different to that from a previous TB episode defined as relapse or reinfection, 
respectively. Recent estimates suggest that 51 % of notified retreatment cases in South Africa were 
due to relapse (WHO, 2014).  
 
Weakened immune responses and low CD4 counts, characteristic of HIV infection, are significant 
triggers of reactivation disease (Lawn et al. 2005). Other predictors of recurrent TB disease include, 
but are not limited to, poor patient adherence to anti-TB treatment, residual cavitation, TB treatment 
lasting less than 37 weeks (reviewed comprehensively in Panjabi et al. 2007) and reinfection with a 
different strain of M. tuberculosis (Chaisson et al. 2010). Primary drug resistance has also been 
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described as a strong risk factor contributing to TB relapse and treatment failure (Quy et al. 2003). 
M. tuberculosis acquires drug resistance as a result of mutations within the bacterial genome which 
are thought to impose a ‘fitness cost’, usually occurring in the form of reduced growth in vitro or in 
vivo (Schrag et al. 1997). However, the role of M. tuberculosis fitness in the context of recurrence 
remains elusive.  
 
Several studies show that subpopulations of bacteria may evade complete eradication by the 
immune system and establish latency (Gupta et al. 2012). Tuberculous granulomas which primarily 
aid in controlling infection ironically permit survival of latent TB bacilli within infected, inactivated 
cells (Tufariello et al. 2003). The transition of such bacteria into an active, virulent form is termed 
reactivation or relapse (Biketov et al. 2007). A number of mycobacterial factors may induce 
reactivation including resuscitation promoting factors which are thought to play an important role in 
forcing mycobacteria out of a state of dormancy or latency (Biketov et al. 2007). The DosS/DosT-
DosR regulon has been shown to mediate the transition of M. tuberculosis from aerobic to 
anaerobic respiration and may also facilitate the resumption of replication following re-exposure to 
oxygen (Leistikow et al. 2010). 
 
Relapse often occurs 6 to 12 months after treatment completion. In the present study, three patients 
developed relapse 15 to 48 months after successful TB-treatment completion. Patients were HIV-
positive and were receiving highly active antiretroviral therapy (HAART). Here we compare the 
fitness and drug susceptibility patterns of initial and relapse isolates (with identical DNA fingerprint 





This is a subset of a prospective, cohort study investigating the incidence of TB recurrence in adult 
TB/HIV co-infected patients stable on HAART, and who had previously completed therapy for 
pulmonary TB. This study was conducted from June 2005 to August 2013 at the CAPRISA 
eThekwini clinic in KwaZulu-Natal Province, South Africa. All patients received standardized TB 
therapy as per the South African National TB Control Program Guidelines (2005). New TB cases 
were treated with a fixed-drug combination of rifampicin (RIF), isoniazid (INH), ethambutol 
(EMB) and pyrazinamide (PZA) dosed according to weight, for a 2-month intensive phase. The 4-
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month continuation phase included a fixed-drug combination of INH and RIF. Retreatment cases 
received a 60-day intensive phase (including streptomycin), followed by a 100-day continuation 
phase. All patients were initiated on a once-daily antiretroviral therapy regimen; didanosine, 
lamivudine and efavirenz, dosed according to weight. Patients were followed up for 5 years, at 3-
monthly intervals. TB symptoms screening and clinical evaluation were conducted 3-monthly; chest 
x-rays and laboratory evaluations were conducted at baseline and 6-monthly. Patients were deemed 
cured based on the following criteria: completion of TB treatment based on protocol-defined 
uninterrupted TB treatment, with a clinical and radiologic response to TB treatment without two 
adequate sputum samples obtained at or beyond 2 months, including one at or beyond 5 months of 
treatment (Dr. K Naidoo, personal communication). Among 489 patients with a previous TB 
cure/TB treatment completion, 68 (14 %) patients developed recurrent TB. The diagnosis of 
recurrent TB was made microbiologically via induced sputum collected at baseline, every 3 months 
or on suspicion of TB. Sputum smear microscopy and culture were performed on all sputum 
specimens. Routine drug susceptibility testing which became available only after 2008 was 
conducted on cultures. This study was approved by the Biomedical Research Ethics Committee of 
the University of KwaZulu-Natal (BF 051/09).  
 
Clinical isolates 
Fifteen pairs of initial and recurrent isolates were previously genotyped by IS6110-RFLP typing. Of 
these, three sets of paired isolates (Table 5.1) were selected on the basis of matching RFLP patterns. 
Isolates were grown on Middlebrook 7H11 medium (Difco) supplemented with 10% oleic acid-
albumin-dextrose-catalase (OADC) enrichment (Becton Dickinson) and 0.5% glycerol for 2-3 
weeks at 37 °C. Mycobacterial harvests were heat-inactivated for 30 minutes at 80 °C. Genomic 
DNA was isolated by the cetyltrimethylammonium bromide (CTAB) method with some 
modifications (van Soolingen et al. 2001). RFLP typing was carried out using the method described 
previously (van Embden et al. 1993). Restriction fragment length polymorphism patterns were 
visualized using enhanced chemiluminescence (Amersham Pharmacia, Buckinghamshire, England). 
For each pair, we verified that initial and relapse isolates shared identical RFLP profiles. 
Spoligotyping was performed as previously described (Kamerbeek et al. 1997) using a 






Drug susceptibility testing 
Drug susceptibility testing was performed using the 1% agar proportion method on Middlebrook 
7H10 medium (Difco) supplemented with 10% OADC, 0.5% glycerol and appropriate drugs 
(Sigma) as previously described (NCCLS, 2003). The following concentrations were used: 1.0 
mg/L INH and RIF, 7.5 mg/L EMB, 2 mg/L ofloxacin (OFX) and streptomycin, and 5 mg/L 
kanamycin and ethionamide (ETH). After 3 weeks of incubation at 37 °C, the number of colony 
forming units (CFU) on drug-containing medium was compared with the number on drug-free 
medium. Isolates with growth on the drug-containing medium of > 1% of that on drug-free medium 
were classified as drug-resistant. 
 
Minimum inhibitory concentrations  
Minimum inhibitory concentrations (MIC) were determined in a 96-well plate format using Alamar 
Blue (Invitrogen) as previously described (Franzblau et al. 1998). The following drug concentration 
ranges were tested: for INH and OFX, 0.125 – 32 mg/L; RIF, 0.06 – 16 mg/L; EMB, 0.5 – 128 
mg/L and ETH, 0.003 – 8 mg/L. Wells containing inoculum only (drug-free) served as controls. The 
MIC was defined as the lowest drug concentration at which no colour change from blue to pink 




The following genes were examined in paired isolates:  580 bp of the katG gene, 437 bp of the rpoB 
gene, 863 bp of the embB gene, 670 bp of the pncA gene, 320 bp of the gyrA gene, 1278 bp and 342 
bp of the ethA gene. Template DNA was amplified using Q5 Hot Start High-Fidelity DNA 
Polymerase (NEB, Scientific Group, SA) and primer sequences from previously reported studies 
(Takiff et al. 1994; van der Zanden et al. 2003; Zenteno-Cuevas et al. 2009; Brossier et al. 2011; 
Alexander et al. 2012; Bakula et al. 2013). Polymerase chain reactions (PCR) were performed in a 
25-µl reaction mixture consisting of 1X Q5 Reaction Buffer, 0.4 µM forward and reverse primers, 
1X Q5 High GC Enhancer, 0.2 mM dNTPs, 0.02 U/µl Q5 DNA polymerase and 50 ng of template 
DNA. Nuclease-free water was used as a negative control and the M. tuberculosis laboratory strain 
H37Rv was used as a positive control. Thermal cycling conditions included an initial denaturation 
step at 98 °C for 1.5 min, followed by 35 cycles as follows: denaturation at 98 °C for 10s, annealing 
at 58-70°C (depending on primer set) for 10s and extension at 72°C for 2 min, and a final extension 
step of 2 min at 72 °C. Amplifications were confirmed by gel electrophoresis in 1% agarose gels. 
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Amplified products were outsourced for purification and subsequent sequencing on the 3500XL 
Genetic Analyzer platform (ABI, Life Technologies). Mutations were identified by aligning 
sequences to the M. tuberculosis H37Rv reference (GenBank accession number NC_000962) using 
BioEdit software (Ibis Biosciences, Carlsbad, CA).  
 
Fitness assay 
Isolates were grown from an optical density at 600 nm (OD600) of 0.015 in 25 ml of Middlebrook 
7H9 medium (Difco) containing 10% OADC, 0.5% glycerol and 0.05% Tween-80 (Sigma) as 
previously described (Naidoo and Pillay, 2014). Serially-diluted culture was plated onto triplicate 
Middlebrook 7H11 agar plates and incubated for 21 days at 37 °C. Three independent experiments 
were performed for each isolate pair. OD600 and CFU counts were recorded on days 0 (baseline), 12 
(log-phase) and 20 (late-log phase).  
 
Statistical analysis 
Differences in mean relative fitness indices between initial and relapse isolates on days 12 and 20 
were calculated by one-way analysis of variance (ANOVA) (IBM SPSS Statistics version 22.0, 





Paired isolates from one male and two female patients were analysed. Viral loads and CD4 counts 
were improved at the time of relapse, albeit only a marginal increase in CD4 counts was observed 
for patient three (Table 5.1). Viral load information was missing at the time of initial TB infection 
for patient two however undetectable viral loads were recorded at the time of relapse. Patients one 
and two showed increased body mass indices (BMI) at the time of relapse, whereas the BMI of 
patient three was slightly reduced. Patients one and two both had a previous history of TB disease 
for which they received eight and six months of anti-TB treatment, respectively. These episodes 
occurred prior to enrolling into this study. Both patients presented with their third episode of TB 34 
and 48 months respectively, after successful treatment completion for their second episode of TB 
while in the study. Thus, paired isolates from episodes two and three were analysed for patients one 
and two. Patient three had no past history of TB, received six months of standardised anti-TB 




Among 15 paired isolates obtained during our prospective cohort study, we identified 3 sets of 
paired isolates by RFLP typing, with identical DNA fingerprints (Figure S5.1), representing 




Table 5.1 Patient epidemiological data 
Patient Episode Isolate Missing spacers Genotype Age Gender CD4 count  
(cells/mm3) 
Viral load  
(cpm) 
BMI 
1 2007 74684 21-24, 33-36, 39-40 F15/LAM4/KZN 28 Male 100 73300 18.5 
 2011 11370 21-24, 33-36, 39-40 F15/LAM4/KZN 31  565 342 20.4 
2 2006 066069 1-34 Beijing 37 Female 233 Unknown 21.6 
 2010 102570 1-34 Beijing 42  911 Undetectable 24.5 
3 2005 73078 4-12, 18, 33-36 X3 30 Female 203 83900 26.5 
 2007 05129 4-12, 18, 33-36 X3 31  277 <400 25.8 
 
 
 Table 5.2 Drug resistance profiles of paired isolates 
Pair Isolate (episode) Drug resistancea MICs (µg/mL)b Mutations 
   I  R Et E O  katG rpoB ethA embB gyrA pncA 
1 74684 (initial) IREtEO > 32 16  > 8 > 128 2  S315T L452P - M306V S95T +c in A152 
 11370 (relapse) IREtEO > 32 16  > 8 > 128 2  S315T L452P - M306V S95T +c in A152 
2 066069 (initial) none - - - - - - - - - S95T - 
 102570 (relapse) none - - - - - - - - - S95T - 
3 05129 (initial) IEtO > 32 - > 8 - > 8  S315T - - - S95T - 
 73078 (relapse) IEtO > 32 - > 8 - > 8  S315T - - - S95T - 
a I: isoniazid, R: rifampicin, Et: Ethionamide, E: ethambutol, O: ofloxacin.  




Phenotypic drug resistance  
Drug susceptibility patterns and MICs were identical for initial and relapse isolates (Table 5.2). 
Patient one isolates were phenotypically resistant to INH, RIF, ETH, EMB and OFX. Patient two 
isolates were susceptible to all drugs tested in this study. Patient 3 bore poly-resistant isolates 
(resistance to a combination of two or more drugs that do not constitute MDR) with phenotypic 
resistance to INH, ETH and OFX only.  
 
Mutations associated with drug resistance 
Isoniazid resistance in KZN and X3 paired isolates was associated with the S315T katG mutation 
(Table 5.2). No mutations were identified in the ethA gene, indicating the contribution of other 
genes to ETH resistance. KZN isolates which were phenotypically resistant to RIF and EMB, bore 
corresponding L452P and M306V mutations in rpoB and embB, respectively. Although 
susceptibility to PZA was not tested, the pncA gene was sequenced to identify potential mutations 
associated with PZA resistance. We identified an insertion (+c) at codon 152 of pncA in both KZN 
isolates. No ofloxacin resistance-conferring mutations were detected in gyrA in KZN and X3 




F15/LAM4/KZN and X3 relapse isolates had significantly higher OD600 values than initial isolates 
on day 12 but similar OD600 measurements on day 20 (Figure 5.1). Beijing paired isolates had 
similar OD600 readings on days 12 and 20. Colony forming units counts which are more reliable 
than OD600 for quantifying viable microorganisms, showed nearly identical growth rates for initial 
and relapse isolates on day 12 (Figure 5.2). On day 20, more visible differences were evident 
between initial and relapse isolates of the KZN and X3 genotypes however, these were not 
statistically significant. Interestingly, Beijing isolates grew poorly in laboratory culture, compared 
to KZN and X3 isolate pairs. Statistically significant differences were observed on day 20 between 


















Figure 5.1 Optical density (OD600) measurements for F15/LAM4/KZN (A), Beijing (B) and X3 (C) paired isolates. Data represents the mean 


















Figure 5.2 Comparative growth of paired isolates as measured by colony forming units (CFU) 
counts. Data represents the mean ± SD of three independent experiments, analysed by one-way 
analysis of variance (ANOVA). * P = 0.007, ** P = 0.006. 
 
DISCUSSION 
Patients in this study had developed TB relapse despite their improved health status. This is in 
accordance with other studies which suggest that under favourable conditions i.e. improved CD4 
counts, the risk of TB is still high and that HIV infection may impose further immune impairments 
unrelated to CD4 counts (Lawn et al. 2005). This prompted us to investigate the biological fitness of 
paired isolates as a contributor to relapse in these patients.  
 
Identical drug susceptibility profiles, MICs and resistance-conferring mutations were obtained for 
paired isolates which had matching RFLP and spoligotyping patterns at baseline infection and 
relapse. Taken together, this finding supports the assertion that isolates recovered at the time of 
relapse most likely represents primary-infecting isolates, which under permissive in vivo conditions 
were capable of reactivating from a latent state (Gupta et al. 2012). Growth rates, as measured by 
CFU, were not statistically different for initial and relapse isolates, demonstrating that clinical 
isolates do not necessarily undergo fitness costs during reactivation. 
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Generally, persistent bacilli are harder to eradicate if they exist in necrotic lung regions, are in a low 
metabolic state or exhibit reduced susceptibility to anti-TB drugs (Boshoff and Barry, 2005). The 
most probable explanation for relapse in these patients could be that a subpopulation of infecting 
mycobacteria shifted into a non-replicating (dormant) state, thereby rendering them phenotypically 
resistant to anti-TB drugs (Gengenbacher and Kaufmann, 2012). As a result of standardised sputum 
inspection methods, these bacilli perhaps went undetected and patients were deemed cured. 
Subsequent to termination of anti-TB treatment, some bacilli may have recovered, with unchanged 
fitness, and replicated to high enough bacterial loads causing relapse. Indeed, mutations identified 
in katG and rpoB in the KZN isolates are thought to confer high-level drug resistance whilst 
sustaining mycobacterial fitness (Naidoo and Pillay, 2014). This process may have also allowed for 
the acquisition of compensatory mutations in already drug-resistant isolates which could 
outcompete less fit and less resistant mycobacteria (Andersson and Hughes, 2010), however further 
examination is required. We did not detect any mutations in gyrA, thus OFX resistance in the KZN 
and X3 isolates may be attributable to mutations outside of the sequenced quinolone resistance-
determining region. Intriguingly, the KZN paired isolates demonstrated increased in vitro fitness 
compared with Beijing and X3 pairs, corroborating previous studies which show specific genetic 
backgrounds may cope better with fitness costs associated with drug resistance (Naidoo and Pillay, 
2014; Gagneux et al. 2006). 
 
We cannot conclusively rule out reinfection with the same strain, especially in endemic settings that 
promote the circulation of specific predominant M. tuberculosis strains (Shen et al. 2006). Whole-
genome sequencing of M. tuberculosis isolates from sputum specimens could distinguish highly 
related but genetically distinct strains, affording resolution that is not possible with other 
fingerprinting methods (Bryant et al. 2013). Moreover, the inclusion of additional assays measuring 
fitness would strengthen the findings of this study. Nevertheless, these preliminary findings indicate 
that M. tuberculosis isolates may retain in vitro fitness at the point of relapse, and warrant further 
inspection. This could have significant implications for future TB control programs as retreatment 
cases are often associated with lower cure rates (Murray et al. 1999) and increased risk for the 
development of drug-resistant TB (Costello et al. 1980). Molecular epidemiological tools which 
accurately distinguish between exogenous reinfection and TB relapse, together with the 
development of new, effective anti-TB agents may aid in improved surveillance and management of 
TB, particularly in settings with high incidence rates of TB and HIV. Until improved therapeutic 
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regimens become implemented, lengthier courses of TB therapy may be necessary for reducing the 
number of retreatment cases.  
 
HIV-associated TB is the commonest clinical manifestation of TB in sub-Saharan Africa, with 
ongoing vulnerability to TB previously demonstrated in HIV-infected patients. Population studies 
have further suggested that wide-scale ART access will reduce TB incidence, however this study 
demonstrates that the individual risk of relapse after successful TB treatment completion, in stable 
patients on HAART, still exists.  
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SYNTHESIS AND FUTURE WORK 
MDR-TB cases comprised a small proportion (~ 5%) of total TB cases in 2014 (WHO, 2015). 
However, given that biological fitness is a primary determinant in the transmission of M. 
tuberculosis, and that low- or no- cost mutations are frequently selected for in clinical isolates, the 
potential for MDR and even XDR-TB to expand is an imperative concern. While the Beijing 
genotype is associated with MDR and XDR-TB globally and in South Africa, non-Beijing strains 
propel the transmission of drug resistance in the KZN Province (Muller et al. 2013; Gandhi et al. 
2014; Cohen et al. 2015). To test the hypothesis that the enhanced fitness of specific genotypes is 
associated with beneficial resistance-conferring mutations and/or compensatory mutations, four 
clinically-relevant genotypes were selected for evaluation of fitness. These included susceptible, 
MDR and/or XDR strains from F15/LAM4/KZN, Beijing, F11 and F28 genotypes. 
 
The first objective of this research was divided into two parts: (1) to determine the laboratory fitness 
of these strains using a number of growth, viability and competition assays, and (2) to correlate 
phenotypic findings with mutations in selected genes associated with drug resistance. Susceptible 
and resistant F15/LAM4/KZN and F28 strains had shown similar growth kinetics as measured in 
axenic experiments, whilst Beijing and F11 MDR strains exhibited significantly reduced fitness 
relative to susceptible strains. Sequencing of common genes associated with INH, RIF, OFX and 
KAN resistance revealed the presence of low- or no-cost mutations in F15/LAM4/KZN and F28 
resistant strains, whilst the Beijing MDR strain harboured a less frequently-occurring katG mutation 
associated with a high fitness cost. The absence of a mutation in the sequenced region of katG 
indicated that a less frequently-occurring mutation with high costs were present in the F11 MDR 
strain. 
 
During competitive growth assays, apparent differences were revealed even amongst genetically 
similar strains. This highlights the importance of carefully selecting comparator strains to avoid bias 
when assessing laboratory fitness. The use of standardised reference strains alone would bias results 
i.e. a commonly-used reference strain, H37Rv, was isolated over a century ago and its serial passage 
in laboratory culture may have compromised its use as a comparator strain in fitness studies.  
 
An interesting phenomenon was observed in co-culture experiments with susceptible and resistant 
strains, where growth was amplified relative to axenic cultures. This phenomenon was applicable to 
all four genotypes and was not reported previously in M. tuberculosis. Similar to M. tuberculosis, 
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Staphylococcus aureus strains which acquire drug resistance-conferring mutations often undergo 
fitness costs. A study by Hammer et al. (2014) showed that co-culture of two distinct S. aureus 
mutants led to the improvement of fitness to that of wild-type levels. This synergism was attributed 
to the exchange of metabolites between mutants which not only enhanced growth but also increased 
the production of virulence factors and pathogenic effects (Hammer et al. 2014). Likewise, some 
sort of metabolite exchange may take place between susceptible and resistant M. tuberculosis 
strains during co-culture. Attempts to elucidate the mechanism behind this synergistic growth 
phenomenon were difficult without a defined genetic target, thus these findings in M. tuberculosis 
remain solely observational. Nevertheless, the implications of this phenomenon in TB patients are 
far-reaching as many studies have reported the existence of multiple-strain infections in South 
Africa (Richardson et al. 2002; Warren et al. 2004; van Rie et al. 2005; Cohen et al. 2011). The 
findings by Hammer et al. (2014) were extended to the interspecies level, whereby members of the 
human microbiota enhanced the fitness of S. aureus mutants (Hammer et al. 2014). Thus, further 
studies examining the influence of interspecies interactions on the growth of M. tuberculosis may 
provide significant insight into host pathogenesis.  
 
The second objective expanded on the first, by addressing the role of genome-wide mutations in 
drug resistance, compensation and fitness of selected clinical strains. WGS analysis provided an 
understanding of some of the phenotypes that were observed in the first study. Firstly, resistant 
KZN strains demonstrated heterogeneous fitness when paired with different susceptible competitors 
(V9124 and V4207), indicating that susceptible strains differed in fitness. Mapping of V9124 to 
V4207 revealed a total of 43 SNPs, accounting for their differences in fitness. Secondly, WGS 
helped uncover mutations that were missed during preliminary amplicon sequencing i.e. the rare 
katG mutation associated with high-level INH resistance (1 µg/ml) in the F11 MDR strain and 
intragenic rpoB mutations associated with compensation in MDR and XDR KZN strains. This 
highlights the disadvantage of solely targeting ‘hot-spot’ genetic regions, as other significant 
mutations related to drug resistance could be overlooked.  
 
Of the 10 sequenced strains, two (V1435 and KZN605) were previously sequenced by the Broad 
Institute. These strains were re-sequenced to ensure comparability to other strains cultured under the 
same conditions. Using WGS, a variety of drug resistance-encoding mutations were indentified, 
including a novel ubiA mutation in the F28 MDR strain. Stepping-stone mutations related to EMB 
resistance are of recent interest (Safi et al. 2013), thus the significance of this mutation warrants 
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further research. Some isolates carry resistance without defined gene mutations, suggesting that 
other mechanisms (e.g. efflux pumps) are at play (Choudhuri et al. 2002; Ramon-Garcia et al. 2009; 
Balganesh et al. 2010). Although resistance was explained by mutations in well-characterised genes 
for all resistant strains included in this study, efflux pumps were explored as an alternate source of 
resistance. With the exception of KZN genotype strains which harboured mutations specific to 
resistant phenotypes, a large proportion of mutations in genes encoding efflux pumps were common 
to both susceptible and resistant strains. This underscores the need for further studies which 
demonstrate clear relationships between drug resistance and spontaneous mutations related to efflux 
pumps. 
 
Whereas some groups perform WGS on single colonies which may not be a true representation of 
the genomic diversity within a sample, others which sequence a complete M. tuberculosis 
population may minimize the amount of diversity present in a sample (Black et al. 2015). However, 
this is dependent on read depth, a feature which can be improved so as to not miss any 
heterogeneity at target alleles (Black et al. 2015). In this study, a selection of low-frequency alleles 
in rpoB, rpoC and sigA genes were verified by Sanger sequencing, of which all proved to be true 
variants. These mutations highlight the versatility of M. tuberculosis organisms which are able to 
lose or gain mutations in response to changing selective pressures (Black et al. 2015). It also raises 
the question of how genetic heterogeneity shapes treatment outcomes, especially in high TB-burden 
regions such as South Africa, where antibiotic programmatic selection exists.  
 
Whole-genome sequencing also afforded valuable insights into the distribution of nSNPs in specific 
genes encoding virulence factors. Beijing, F11 and F28 genotypes clustered together with 
(different) nSNPs in the mas gene. The F15/LAM4/KZN genotype was set apart from other 
genotypes with nSNPs in the mmaA4 gene only. Although spontaneous mutations in the mmaA4 
have been implicated in thiacetazone resistance (Alahari et al. 2009), this mutation was common to 
both susceptible and resistant KZN strains. Using a transposon library of mutants in macrophages, 
Dao et al. (2008) detected that the inactivation of the mmaA4 gene resulted in increased induction of 
IL-12p40 and attenuation of the mutant in macrophages and mice. Thus, further studies elucidating 
the role of mmaA4 mutations may reveal interesting data related to IL-12-mediated host responses 
and virulence (Dao et al. 2008). Taken together, WGS provided significant insights into the genetic 
diversity among M. tuberculosis strains, on the basis of both drug resistance and genetic 
background. As WGS by itself is not capable of dissecting strain-specific differences in 
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transmissibility or virulence, future studies should aim to integrate clinical data with genomic 
sequence data to improve our understanding on the success of M. tuberculosis. Moreover, declining 
costs of WGS means that this technology could be implemented on a wider basis, therefore 
necessitating the development of user-friendly software and accessible genomic databases (Takiff 
and Feo, 2015). 
 
Because in vitro assays do not fully mimic in vivo conditions, the fitness of M. tuberculosis strains 
was examined in a human monocytic-like cell line (THP-1) as part of the third objective.  The use 
of macrophages derived from transformed monocytic cell lines are suitable representations of early 
stages of infection with M. tuberculosis (Theus et al. 2005). Uptake efficiencies, intracellular 
replication and cytokine induction were assessed at two time points. Increased or equal intracellular 
replication was demonstrated for resistant KZN strains relative to the susceptible KZN strain in 
macrophages. Previous studies assessing the virulence of KZN strains showed increased invasion 
and necrosis of A549 cells by XDR strains (Ashiru et al. 2010; Ashiru and Sturm, 2015). Increased 
levels of TNF-α were produced by XDR strains relative to other strains. These strains may exploit 
the secretion of TNF-α for tissue destruction and facilitate its transmission to other hosts. During the 
experimental phase of this thesis, another research group assessed the virulence of F15/LAM4/KZN 
genotype strains in a murine model and found an indirect relationship between drug resistance and 
virulence, with XDR strains demonstrating the lowest virulence (Smith et al. 2014). While all but 
one strain tested in Smith et al. (2014) differed from those included in this thesis, it is plausible that 
macrophage findings do not embody that of mouse models, and necessitates further research.  
 
Beijing and F11 MDR strains did not undergo intracellular replication costs relative to susceptible 
strains, which was surprising given their reduced in vitro fitness. However, these strains differed in 
their cytokine responses, an observation probably associated with differences in drug 
susceptibilities rather than bacillary burden. As with in vitro assays, the F28 MDR strain displayed 
comparable fitness to the susceptible strain in THP-1 macrophages. While these strains elicited 
similar levels of most cytokines, the susceptible strain produced significantly higher levels of IL-1β, 
IL-6 and GM-CSF compared with the MDR strain. An interesting observation was that the 
susceptible F28 strain had very similar replication and cytokine responses to H37Rv, with only one 




To understand fitness in the context of TB recurrence, the last aim assessed the drug resistance 
patterns and growth kinetics of paired isolates using microbiological and molecular techniques. In 
the light of improved health status of HIV patients at the time of TB relapse, the in vitro fitness of 
M. tuberculosis isolates was investigated as a putative contributor to relapse. Isolates were collected 
from three HIV-positive patients who had successfully completed anti-TB treatment but later 
developed relapse.  Matching fingerprint patterns of paired isolates were re-confirmed by IS6110-
RFLP typing and spoligotyping. Isolates did not develop additional drug resistance and MICs 
remained unchanged at the point of relapse. Furthermore, initial and relapse isolates had 
indistinguishable growth kinetics supporting that M. tuberculosis can reactivate without significant 
changes in fitness, despite prolonged exposure to anti-TB drugs and host immunity. To the best of 
our knowledge, this has not been shown before in relapse isolates. Interestingly, pre-XDR KZN 
isolates had higher fitness (as measured by CFU) than pan-susceptible Beijing paired isolates, 
verifying that the KZN genotype does not undergo significant fitness costs in resistant forms. 
Recent WGS analysis of recurrent isolates revealed few (if any) SNP differences between initial and 
relapse isolates whereas strains causing reinfection differed from initial isolates by at least 1306 
SNPS (Guerra-Assuncao et al. 2015). While their findings emphasise the usefulness of WGS for 
strain differentiation, it also highlights the preservation of genomic diversity in relapse isolates 
which would translate into retained potential for transmission to other hosts.  
 
LIMITATIONS 
Given the diversity of circulating genotypes in the KZN Province and other regions of South Africa, 
it is acknowledged that the inclusion of additional strains and genotypes (i.e. CAS, EAI1-SOM, X 
and T) would strengthen the findings of the thesis. Furthermore, due to financial constraints, WGS 
was only possible for a few strains within each genotype. One limitation of using the Bio-Plex Pro 
™ Human Cytokine 17-plex assay (Bio-Rad) was the overall low sensitivity for some analytes. 
Given the exorbitant cost of this kit, validation by a more sensitive method i.e. enzyme-linked 
immunosorbent assay (ELISA) would have proven too costly. Additional time points may have 
provided more insight into the replication and cytokine induction of clinical strains in macrophages. 
While interesting observations were made in the study of relapse isolates, additional time intervals 







This study showed that the enhanced fitness of drug-resistant KZN and F28 genotype strains is due 
to the presence of beneficial resistance-conferring mutations and compensatory mutations, while the 
reduced fitness of MDR Beijing and F11 strains is associated with high cost katG mutations and the 
absence of compensatory mutations. In support of this, the predominance of KZN and S (or F28) 
strains among MDR and/or XDR cases have been well-documented, whereas Beijing and LAM3 (or 
F11) strains frequents among susceptible TB-cases in KZN (Pillay and Sturm, 2007; Andrews et al. 
2008; Pillay and Sturm, 2010; Gandhi et al. 2014; Cohen et al. 2015). Moreover, the existence of 
XDR KZN predecessors prior to the HIV epidemic in South Africa indicates that the selection of 
drug resistance can take place even in low-prevalence HIV settings (Cohen et al. 2015). Taken 
together, this highlights the importance of TB surveillance systems which may prevent future 























































Table S2.1 Baseline (Day 0) CFU/ml readings corresponding to an OD600nm of 0.015 in growth 
assays 
 
Genotype family Strain Drug resistance profile CFU/ml 
F15/LAM4/KZN V9124 S 2.50E+06 
  V4207 S 3.10E+06 
  V1435 MDR 1.90E+06 
  V2475 MDR 2.05E+06 
  KZN605 XDR 1.50E+06 
  X162 XDR 1.00E+06 
Beijing B910 S 2.70E+06 
  B1528 S 2.05E+06 
  R 35 MDR 2.10E+06 
  R 283 MDR 1.70E+06 
F11 R 490 S 3.75E+05 
  R 271 MDR 3.65E+05 
F28 R 104 S 7.00E+05 
  R 443 MDR 8.00E+05 
  R 262 XDR 1.55E+06 





Table S2.2 Relative fitness index of drug-resistant strains in comparison to drug-susceptible strains and H37Rv on day 24 
 
Genotype family Strain Drug resistance profile Relative Fitness Index Susceptible competitor 
F15/LAM4/KZN V1435 MDR 1.05 ± 0.23 V9124 
      1.14 ± 0.15 V4207 
      0.86 ± 0.10 H37Rv 
  V2475 MDR 0.93 ± 0.13 V9124 
      1.02 ± 0.08 V4207 
      0.78 ± 0.06 H37Rv 
  KZN605 XDR 0.92 ± 0.17 V9124 
      1.00 ± 0.09 V4207 
      0.76 ± 0.04 H37Rv 
  X162 XDR 1.25 ± 0.15 V9124 
      1.36 ± 0.05 V4207 
      1.04 ± 0.06 H37Rv 
Beijing R 35 MDR 1.01 ± 0.04 B910 
      0.99 ± 0.02 B1528 
      0.94 ± 0.04 H37Rv 
  R 283 MDR 1.08 ± 0.01 B910 
      1.05 ± 0.04 B1528 
      1.01 ± 0.06 H37Rv 
F11 R 271 MDR 0.99 ± 0.06 R 490 
      0.83 ± 0.04 H37Rv 
F28 R 443 MDR 0.98 ± 0.02 R 104 
      1.01 ± 0.07 H37Rv 
  R 262 XDR 0.91 ± 0.04 R 104 
      0.93 ± 0.04 H37Rv  





Table S2.3 Significant p-values for the OD and CFU competition assays 
 
Genotype family Pairwise competition OD assay p-value CFU assay p-value 
F15/LAM4/KZN V9124 (S) > V1435 (MDR) 0.035 0.034 
  V1435 < V4207 (S) + V1435  0.038   
  V9124 > V2475 (MDR) 0.022   
  V4207 > V2475  0.013   
  V9124 > KZN605 (XDR) 0.027   
  V4207 > KZN605  0.035 0.044 
  X162 (XDR) < V4207 + X162 0.045   
Beijing B910 (S) > R35 (MDR) 0.048 0.01 
  R35 < B910 + R35 0.016   
  B1528 (S) > R35 0.044   
  B910 > R283 (MDR)   0.027 
  R283 < B910 + R283 0.016   
  B1528 > R283 0.043   
F11 R490 (S) > R271 (MDR)   0.034 
  R271 < R490 + R271 0.026   
A p-value less than 0.05 was considered significant.  > represents more fit, < represents less fit. S: susceptible;  
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Figure S2.1 Optical density measurements of clinical strains in independent cultures. Growth rates 
were determined for the F15/LAM4/KZN (A), Beijing (B), F11 (C) and F28 (D) genotype families. 
Data represents the mean ± standard deviation of triplicate cultures per strain. S: susceptible; MDR: 
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Figure S2.2 Absorbance measurements of clinical strains in independent cultures in the Alamar 
Blue assay. Metabolic rates were determined for the F15/LAM4/KZN (A), Beijing (B), F11 (C) and 
F28 (D) genotype families. Data represents the mean ± standard deviation of triplicate cultures per 






























Figure S2.3 Optical density measurements for susceptible strains paired with MDR (A) and XDR (B) F15/LAM4/KZN strains in 
competitive growth assays. Data represents the mean ± standard deviation of duplicate experiments. S: susceptible; MDR: multidrug-
resistant; XDR: extensively drug-resistant 
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Figure S2.4 Optical density measurements for susceptible strains paired with Beijing MDR strains R35 (A) and R283 (B) in competitive 















Figure S2.5 Optical density measurements for F11 (A) and F28 (B) clinical strains in competitive 
growth assays. Data represents the mean ± standard deviation of duplicate experiments. S: 










































Figure S2.6 Colony forming units counts for susceptible strains paired with MDR (A) and XDR (B) F15/LAM4/KZN strains in competitive 
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Figure S2.7 Colony forming units counts for Beijing susceptible strains paired with MDR strains 
R35 (A) and R283 (B) in competitive growth assays. Data represents the mean ± standard deviation 
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Figure S2.8 Colony forming units counts for F11 (A) and F28 (B) clinical strains in competitive 
growth assays. Data represents the mean ± standard deviation of duplicate experiments. S: 






















Table S3.1 Oligonucleotide primers used for SNP verification by Sanger Sequencing 
Oligo 5’ – 3’ sequence Product size (bp) Annealing temperature (°C) 
katG_L gccggtcaagaagaagtacg 591 67 
katG_R ctcttcgtcagctcccactc   
rpoB_L1 ctgatccaaaaccagatccg 440 64 
rpoB_R1 tacacgatctcgtcgctaac   
embB_L2 cgacgccgtggtgatattcg 863 70 
embB_R2 ccacgctgggaattcgcttg   
pncA_L3 ggcgtcatggaccctatatc 670 64 
pncA_R3 caacagttcatcccggttc   
rpoC_L agaacatcaagagcgccaag 223 66 
rpoC_R atctggtcaccgtcgaagtc   
sigA_L gcagatacgacgcactgaaa 947 66 
sigA_R ggctagctcgacctcttcct   
rpoB_L agctgagccaattcatggac 239 65 
rpoB_R cgtttcgatgaacccgaac   
1Ao W, Aldous S, Woodruf E, Hicke B, Rea L, Kreiswirth B, Jenison R. Rapid detection of rpoB gene mutations conferring rifampin 
resistance in Mycobacterium tuberculosis. J Clin Microbiol. 2012; 50: 2433-2440. 2Bakuła Z, Napiórkowska A, Bielecki J et al. 
Mutations in the embB gene and their association with ethambutol resistance in multidrug-resistant Mycobacterium tuberculosis clinical 
isolates from Poland. Biomed Res Int 2013; in press. http://dx.doi.org/10.1155/2013/167954. 3Alexander DC, Ma JH, Guthrie JL et al. 
Gene sequencing for routine verification of pyrazinamide resistance in Mycobacterium tuberculosis: a role for pncA but not rpsA. J Clin 











Table S3.2 Summary statistics clinical strains mapped to closely-related reference genomes 
 
a Mapped to the KZN-V4207 reference genome (4,394,985 bp); b mapped to the HN878 reference genome (4,404,672 bp);  c mapped to the F11 reference genome (4,424,435 
bp). 
 V9124 a V1435  a KZN605  a X162  a B910  b R35  b R490  c R271  c 
Mapped Reads 1,830,877 937,477 999,617 1,055,628 899,721 2,018,291 1,406,634 2,681,225 
% of total reads 98.88 98.55 98.94 99.10 98.19 98.75 97.70 98.41 
Average read length 265.15 232.95 225.41 235.45 230.76 243.35 188.51 193.25 
Unmapped Reads 20,759 13,837 10,689 9,542 16,555 25,461 33,112 43,371 
% of total reads 1.12 1.45 1.06 0.90 1.81 1.25 2.30 1.59 
Average read length 285.21 268.05 278.23 282.43 261.55 274.64 198.23 207.32 
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 V9124 V1435 KZN605 X162 B910 R35 R490 R271 R104 R443 
Mapped Reads 1,827,320 935,638 997,781 1,053,750 901,327 2,018,291 1,401,910 2,672,172 749,682 765,817 
% of total reads 98.69 98.35 98.76 98.93 98.37 98.75 97.37 98.08 98.53 98.24 
Average read length 265.15 232.93 225.40 235.44 230.88 243.39 188.50 193.23 228.92 234.04 
Unmapped Reads 24,316 15,676 12,525 11,420 14,949 25,461 37,836 52,424 11,196 13,749 
% of total reads 1.31 1.65 1.24 1.07 1.63 1.25 2.63 1.92 1.47 1.76 
Average read length 282.44 265.20 270.97 275.33 258.15 271.56 197.38 205.96 253.78 263.66 
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Table S3.4 Polymorphisms in re-sequenced V1435 relative to previously sequenced KZN 1435 




TBMG_00302  predicted protein 1701_1702 ins G P568fs 
TBMG_00540 menA 1,4-dihydroxy-2-naphthoate 
octaprenyltransferase  
701_702 ins C A234fs 
TBMG_00782  conserved hypothetical protein 547 del C H183fs 
TBMG_00937  transferase 1139_1140 ins C T380fs 
TBMG_01038 ppsD phenolpthiocerol synthesis type-I 
polyketide synthase  
3823 del A I1275fs 
TBMG_01735 kasA 3-oxoacyl-[acyl-carrier protein] 
synthase 1  
1001_1002 ins C A334fs 
TBMG_02215 malQ 4-alpha-glucanotransferase  1342 del C P448fs 
TBMG_02275 folP2 dihydropteroate synthase 2  632 del C P211fs 
TBMG_04073  conserved hypothetical protein 809_810 ins G A270fs 
TBMG_04086 trcS two component system sensor 
histidine kinase  
873_874 ins C P292fs 
TBMG_03038  conserved hypothetical protein 26delG R9fs 
TBMG_03046  monooxygenase 65_66 ins C R22fs 
TBMG_04096  monooxygenase 1173 del C P391fs 
TBMG_03128  conserved hypothetical protein 1378_1379 ins C A460fs 
TBMG_03778  conserved hypothetical protein 468 del G G156fs 













Table S3.5 Polymorphisms in re-sequenced KZN605 relative to previously sequenced KZN 605 
Gene Function Nucleotide change Amino acid change 
TBXG_000209 Conserved hypothetical protein 62delG G21fs 
TBXG_001385 Conserved hypothetical protein 863delT F288fs 
TBXG_001918 rifB protein 425delA E1419fs 
TBXG_002105 Conserved hypothetical protein 293delG R98fs 
TBXG_002696 Conserved hypothetical protein 552delA K184fs 
TBXG_003461 Conserved hypothetical protein 799CT A267T 
TBXG_003898 Conserved hypothetical protein 445G N149H 
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Figure S5.1 IS6110-RFLP images for patient isolates. (A) Lanes 1-2: F15/LAM4/KZN isolates 
74684 and 11370, respectively; lane 7: H37Rv control; lane 8: lambda DNA cut with HinDIII. (B) 
Lanes 1-2: Beijing isolates 066069 and 102570, respectively; lane 3 and 18: X3 isolates 05129 and 
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